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ABSTRACT
SSRI-Induced Emotional Blunting: A Study of Cognitive Changes in Pharmaceutically Treated
Depression
by
Carly Tocco
Advisor: Claudia Brumbaugh, PhD
Objective: In recent years, approximately 12.7% of the American population are on a
prescribed antidepressant medication. Selective Serotonin Reuptake Inhibitors (SSRIs) are a
widely used pharmacological treatment for depressive and anxiety disorders, primarily due to
their tolerance levels, mild side effects in comparison to other antidepressants, and broad range
of clinical indications. However, there are still numerous concerns about SSRIs’ ability to
improve depressive symptoms without adding side effects such as sexual dysfunction,
gastrointestinal upset, and a restricted range of emotions. Although patients typically claim that
they have less emotional pain while on SSRIs than they do during a depressive episode, they also
report feeling constrained in the range of emotions they experience, such as the inability to cry or
feel enjoyment. When linked to antidepressant treatment, this phenomenon has been described as
emotional blunting, or a numbing of emotion. While emotional blunting has been established
qualitatively, detecting emotional blunting can be difficult for both patients and clinicians since
patients may have little insight about the side effect. This study specifically seeks to address gaps
in the literature by collecting information on subjects with long-term SSRI use for depression.
This work explores the breadth of emotional blunting in long-term SSRI-users by determining if
emotional blunting can alter cognitive processing of emotional information.
Participants and Methods: One hundred and twenty-two adults (61 controls and 61 SSRI-users
with remitted depression) participated in an online survey. SSRI-users reported on emotional
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blunting, mood, demographic characteristics, and SSRI-related side effects including sexual
dysfunction. All participants were asked to identify emotional expressions via a facial Affect
Naming task and attend to emotionally charged words with accuracy and speed via an Emotional
Stroop task.
Results: Findings revealed that SSRI-users who reported sexual dysfunction were more likely than
SSRI-users without sexual side effects to experience SSRI-induced emotional blunting. Contrary
to hypotheses, there were no differences in identifying or processing emotional stimuli between
controls and SSRI-users, between SSRI-users with and without subjective emotional blunting, or
between SSRI-users with or without sexual dysfunction.
Discussion: The connection between sexual dysfunction and emotional blunting in long-term
SSRI-users has been established and needs further exploration, as the two side effects may follow
similar biological pathways and have relevant clinical implications on pharmacologically treating
depression. Further study of the overlap between sexual dysfunction and emotional blunting will
allow prescribers to find optimal dosages while taking into consideration the significant social side
effects demonstrated in many long-term SSRI-users. Other clinical implications include the need
to elucidate objective and accessible ways to measure SSRI-induced emotional blunting in longterm SSRI-users. While emotional blunting in SSRI-users was not detectable through cognitive
assessments in the current study, physiological changes in SSRI-users may provide an objective
way to measure emotional blunting, as these reactions are less likely to be impacted by conscious
awareness and may be more sensitive to subtle nuances. Ultimately, it is crucial that antidepressant
prescribers become more aware of emotional blunting, recognize its overlap with sexual
dysfunction, and find a way to objectively track it over time in order to provide optimal care to
patients with depression.
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1. Introduction
In recent years, approximately 13% of American adults are on a prescribed antidepressant
medication (Kantor et al., 2015). Selective Serotonin Reuptake Inhibitors (SSRIs) are the firstline pharmacological treatment for depressive disorders, primarily due to their tolerance levels,
mild side effects in comparison to other antidepressants, and broad range of clinical indications
(McCabe et al., 2010; Ferguson, 2001; Taylor et al., 2006). Even with mild side effect profiles,
many patients on these medications still report non-adherence to treatment because of adverse
and bothersome side effects (Fortney et al., 2011). Concerns about SSRIs’ ability to improve
depressive symptoms without adding side effects, such as sexual dysfunction, gastrointestinal
upset, and restricted range of emotions, continues to be scrutinized.
Although patients typically claim that they have less emotional pain while on SSRIs than
they do during a depressive episode, they also report feeling constrained in the range of emotions
they experience, such as the inability to cry or feel enjoyment. When linked to antidepressant
treatment, this phenomenon is described as emotional blunting or a numbing of emotion
(Goodwin et al., 2017). While the mechanisms behind emotional blunting have not yet been
determined, a substantial portion of patients taking SSRIs report diminished emotions and an
overall new onset of an apathetic disposition (Fisher et al., 2005). Since depression is such a
complex disorder – one that is an amalgamation of genetic, neurochemical, neuropsychological,
cognitive, and affective domains – it is important to additionally recognize SSRI-induced
changes in cognitive and emotional processing that are distinct from depression symptoms.
This study focuses on the emotional side effects of SSRIs that have been anecdotally
recorded in the past (Barnhart et al., 2004; Garland & Baerg, 2001; Price et al., 2009).
Currently, the literature on emotional blunting has limited empirical data to support this
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phenomenon beyond self-report. To better quantify emotional blunting, the current work will
measure differences in accuracy and speed of processing emotional information as a function of
SSRI use. Most studies to date have looked at acute administration of SSRIs in healthy subjects
when assessing cognitive changes and side effects. To generalize to real-world SSRI use, this
study will look at cognitive changes in individuals prescribed SSRIs for depression who are on
the drug for at least two months. Using these inclusion criteria, the results of this study will
illuminate potential ways to objectively measure emotional blunting in long-term SSRI-users.
1.1 Emotional Blunting
Approximately 20% of patients prescribed an SSRI report new onset of apathy, and 16%
describe a loss of ambition after starting the drug (Bolling & Kohlenberg, 2004), though a more
recent study showed that 46% of antidepressant users reported emotional blunting (Goodwin et
al., 2017). A large international study with 1,340 participants spanning 38 countries asked longterm antidepressant users about adverse effects “as a result of taking the antidepressant.” Results
revealed that 71% of antidepressant users reported feeling emotionally numbed, 66% reported
‘not feeling like myself’, and 60% reported a reduction in positive feelings, which are all
hallmark components of emotional blunting (Read & Williams, 2018).
Emotional blunting is a wholly subjective phenomenon defined as a reduction in
sensitivity in emotional responsiveness to situations where an emotional response would be
appropriate, similar to indifference (Price & Goodwin, 2009; Sansone & Sansone, 2010). Over
the last few decades, the emotional side effects of SSRI-usage have become more widely
recognized and are identified by signs of apathy, a lack of motivation, and a lack of appropriate
concern for relationships and interpersonal situations (Price et al., 2009). These altered emotional
responses are widespread and affect various domains of a person’s life, such as work, school, and
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close personal relationships at home (Opbroek et al., 2002; Price et al., 2009). Emotional
blunting caused by SSRIs may inhibit individuals from feeling their best because blunting
diminishes a person’s ability to feel pleasure and can cause a “numbing” of all emotions,
including positive ones, such as happiness and joy. Past fMRI research where single doses of
antidepressants were administered acutely demonstrated diminished positive emotional responses
in SSRI-users (Takahashi et al., 2005). Along with changes in emotional experiences, SSRIinduced emotional blunting often occurs with distinct dose-dependent features. Individuals on
higher doses are more likely to experience a behavioral or emotional indifference/apathy
(Barnhart et al., 2004). With this said, SSRI-induced emotional blunting is completely reversible
by lowering dosage or discontinuing the medication (Barnhart et al., 2004). Although many
patients deal with these side effects, little is known about the breadth of SSRI-induced emotional
blunting (Garland & Baerg, 2001; Price et al., 2009).
Past research has examined SSRI-induced changes in neural reaction and circuitry. One
study looked at changes in amygdala activation before and after 12 weeks of SSRI use. Results
showed increased amygdala activity in response to positive stimuli and decreased amygdala
activity in response to negative stimuli (Young et al., 2020). Beyond the amygdala, research
demonstrates that even just days of SSRI treatment can alter frontal cortex activity in response to
emotional stimuli. For example, McCabe and colleagues found that SSRI administration for
seven days in healthy controls diminished orbitofrontal and medial frontal neural response to
both positive and negative stimuli (McCabe et al., 2010). Meta-analyses examining the role of
serotonin in emotional processing have shown that central serotonin availability and transmission
modulates the neural response to both positive and aversive stimuli to brain regions known to be
involved in reward processing such as the amygdala and frontal lobe (Macoveanu, 2014).
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With emotional blunting documented anecdotally through case studies and via newer
technology, such as fMRI, looking at simpler ways to measure blunting is pertinent to adequately
understanding how SSRI-induced neural circuitry changes impact overall functioning. By
assessing cognitive differences in emotional processing, it would be possible to have a more
complete understanding of SSRIs’ effects on the mind as well as provide a quick and costeffective way to test for the presence of emotional blunting, track it over time, and determine a
risk/benefit analysis of dose titration in patients taking this medication. To assess for blunting
during their appointments, patients could easily complete brief cognitive tasks, the same way
they update their demographic information or fill out self-report measures of depression.
Likewise, by recording baselines and performing serial follow-up assessments, cognitive
responses to emotional stimuli could be tracked over time and assessed alongside dosage and
brand changes, much like the way depression symptoms are tracked using self-report measures
such as the Beck Depression Inventory (Beck et al., 1996). For example, if a person reports new
onset feelings of distance from their romantic partner, a prescriber could refer to previous
cognitive evaluations and compare test data to the patient’s current cognitive performance. This
process would emulate the way neuropsychologists track changes in memory over time for
patients with neurodegenerative diseases such as dementia or epilepsy (Amarigilio et al., 2015;
Sen et al., 2018). Thus, cognitive assessment would allow for a preventative approach to
emotional blunting, possibly even before the patient is aware of its occurrence, allowing
prescribers to connect social disruptions to potential emotional blunting.
1.2 Accurate Measurement of Emotions
Past research demonstrates that consciously reporting “how we are feeling” may not be
an accurate way of assessing emotions, as it may alter autonomic system processes that produce
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authentic emotional responses. Given this concern, self-report is not ideal in assessing emotions
as it can alter the underlying biological aspects of emotion (Scherer, 2005; Kassam & Mendes,
2013). Previous attempts to steer away from self-report when acquiring data on emotions have
been made for many decades. Past work addressing apathy and depression used caregiver report
instead of self-report, as these clinical syndromes can inherently cause reduced awareness of
change (Zahdone & Tremont, 2012) though caregiver report still remains subjective. Previous
attempts to steer away from self-report when acquiring data on emotions have been made to
remove subjective confounds altogether. For example, relationships between viewing emotional
pictures or words and changes in cardiovascular and electrodermal responses are well
documented (Bernat et al., 2001; Lang et al., 1993). Using cognitive measures instead of selfreport to study emotion may provide more accurate data, as performance on cognitive tasks is
freer from self-awareness or conscious rumination (Kassam & Mendes, 2013). For example,
relationships between viewing emotional pictures and changes in cardiovascular and
electrodermal responses are well documented (Bradley et al., 1996; Bernat et al., 2006).
Similarly, past research has looked at facial muscle movement to assess facial expressions while
viewing emotional pictures to determine emotional responsiveness (Lang et al., 1993).
Beyond lacking the ability to tap into biological aspects of emotions, self-report on
emotional expressivity, intensity, and appropriateness is not reliable because many patients are
not consciously aware of their emotional state. Regarding SSRI-induced blunting, previous
research has documented the insidious onset of emotional blunting and how it often goes
unnoticed, making the use of objective measures, such as reaction times or response inhibition on
cognitive tasks, beneficial in detecting emotional blunting and even more necessary (Price et al.,
2009). Some studies have demonstrated that SSRI-induced emotional blunting often coincides
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with reduced insight, particularly in children and adolescents (Reinblatt & Riddle, 2006). The
emergence of SSRI-induced emotional blunting may also be slightly delayed, making it more
difficult to tie the new blunted affect to the medication itself (Reinblatt & Riddle, 2006).
1.3 Selective Serotonin Reuptake Inhibitors
SSRIs are a class of antidepressants that inhibit 60-80% of serotonin uptake to
efficaciously treat both depressive and anxiety disorders (Alarcon & Prekorn, 2004). The brands
currently available for prescription in the US include Prozac (fluoxetine), Celexa (citalopram),
Lexapro (escitalopram), Paxil (paroxetine), and Zoloft (sertraline). Abnormal serotonin (5-HT)
systems in patients with psychiatric disorders have been documented for decades, making
serotonin the crucial target of pharmacological treatment (Biver et al., 1997). Using central
serotonin agonism, these medications balance low levels of free-flowing serotonin in individuals
with psychiatric symptoms, as low levels of unbound serotonin are linked to depression and
anxiety (Macaluso & Preskorn, 2019). SSRIs and other drugs affecting serotonergic transmission
are effective for the treatment of depression, as they work to keep more serotonin freely lingering
in the blood and block uptake by neurons. While other antidepressants, such as tricyclic
antidepressants and monoamine oxidase inhibitors (MAOIs), exist, SSRIs are preferred by
prescribers as they have a reliable dose-response curve for adverse effects, making it easy to
manage side effects by titration.
1.4 Physical Side Effects of SSRIs
While the current investigation focuses on emotional side effects of SSRI use, it is important
to note that SSRIs are linked to physical side effects as well. For instance, 41% of adult patients
taking SSRIs for depression reported at least one adverse physical side effect of the drug, such as
sleep and gastrointestinal disturbances, nonspecific malaise, and appetite/weight change (Rascati
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et al., 2001). A 2009 study of 700 SSRI-users found that sleepiness and weight gain were the
most common physical symptoms reported in over 100 users, with dry mouth, nausea, tremors,
and dizziness also present (Cascade et al., 2009).
1.5 Sexual Side Effects of SSRIs
Anecdotal data also show that SSRI-use can disrupt many parts of sexual response,
including arousal, excitement, and orgasm (Balon, 2006). Disruption in normal sexual
functioning, for example, a low libido or inability/difficulty to orgasm, is one of the most
commonly reported sexual side effects of SSRI usage (Balon, 2006). One study revealed that
sexual dysfunction was the most common side effect of SSRI use, above and beyond physical
side effects (Cascade et al., 2009). In fact, it is believed that sexual dysfunction affects as many
as 80% of SSRI-users (Gitlin, 1994; Rosen et al., 1999). Unfortunately, SSRI-users with sexual
dysfunction often have co-occurring emotional blunting. One study found that 80% of SSRIusers with sexual dysfunction side effects also reported a dulling of emotions following
treatment (Opbroek et al., 2002). Similarly, a study on SSRI use and physical attraction found
that SSRI-users with combined low libido and difficulties with orgasm were most susceptible to
lowered attraction (Tocco & Brumbaugh, 2018). Based on this high percentage of co-occurrence,
it is possible that the same brain regions affect sexual and emotional functioning with
overlapping neuronal pathways; therefore, SSRI-users who exhibit sexual dysfunction may have
a greater vulnerability for a dulled emotional profile. It is likely that the neurological response is
altered after being exposed to SSRIs, and emotional blunting may result from this change.
1.6 Social Side Effects of SSRIs
Past studies have targeted the social implications of emotional blunting. Examining
young patients, Garland and Baerg (2001) found many physicians reported that after six to eight
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weeks of SSRI treatment, their patients no longer cared about social interactions or consequences
for bad behavior. Other qualitative work reports SSRI-users’ reduced enjoyment of social
interactions, decreased love/affection towards others, and decreased attraction to their current
romantic partner (Price et al., 2009). Some SSRI-users demonstrated detachment during social
situations, including those with partners and children, and some also cared less about themselves
after starting their medication. Other social effects of SSRIs include reduced care or love towards
family members and lower sympathy and empathy for others in general (Price et al., 2009).
SSRI-induced emotional blunting can be so severe in some patients that it produces flat affect
with a mask-like appearance similar to what is seen in Parkinson’s disease (Garland & Baerg,
2001).
While most social side effects of SSRI use are anecdotal, one study recently found that
SSRI-users had lower levels of attraction to novel individuals than to people not on the
medication (Tocco & Brumbaugh, 2018). This finding empirically demonstrates that emotional
blunting socially impacts the way a person taking SSRIs views others. Although SSRIs can have
a significant benefit for mental health, it is important to recognize that they can also cause a
restricted emotional range, which may be harmful for day-to-day functioning. If SSRIs
negatively impact one’s ability to form meaningful social connections due to blunting, then
SSRIs may potentially create new problems related to social isolation or disinterest. Because
blunting occurs secondary to SSRI use, it is possible that pleasure centers in the brain are altered
and obstruct the patient’s ability to notice negative impacts on their social relationships or even
from seeing the benefits of initiating a new relationship. Past research has shown that
relationship initiation requires “bold and direct action” (Cameron et al., 2013), but without a full

8

range of emotions, SSRI-users may lack the initiative to act, potentially leading to lessened
ability to seek out needed support systems (Uchino et al., 1996).
1.7 Classification of Apathy
While the current study will look at cognitive changes associated with SSRI-induced
emotional blunting, it is important to note that emotional blunting has similar features to apathy.
Apathy is a common public health problem that is particularly prevalent in older adults. Some
studies have documented that approximately 49% of individuals over the age of 77 report
symptoms of apathy (Grool et al., 2014). Apathy is associated with a surplus of negative
correlates and consequences such as poor daily functioning, decreased quality of life, caregiver
burden, and poor treatment compliance (Yaeger & Hyer, 2008; Pluck & Brown, 2002). This
phenomenon has been well studied and recorded in conditions such as mild cognitive impairment
(MCI), Alzheimer’s Disease (AD), Parkinson’s Disease (PD), schizophrenia, and depression, all
of which are diseases that impact the prefrontal cortex-limbic system circuitry (MontoyaMurillo, et al., 2019). Apathy was first characterized as a complex neurobehavioral syndrome
with a lack of motivation that affects behavior, emotions, and cognition that is not otherwise
attributable to psychiatric disease or alterations in conscious awareness (Marin, 1991). Marin
postulated that accurate diagnosis of apathy would need to assess action initiation, emotion,
intellectual curiosity, and self-awareness (Marin 1991; Murphy, 2000). Levy and Dubois
attempted to define apathy as a quantitative reduction in self-generated voluntary and purposeful
behavior by characterizing three main areas of disruption that are caused by apathy and their
subsequent pathology. Their research considered apathy to be a multidimensional syndrome,
with disruption in emotional and cognitive processing and a deficit in ‘auto-activation’ (Levy &
Dubois, 2006). The disruption in emotional-affective processing refers to the inability to link
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emotional signals to forthcoming behavior and is thought to be caused by lesions in the orbitalmedial prefrontal cortex or limbic territories such as the ventral striatum of the basal ganglia.
Cognitive processing disruptions due to apathy encompass difficulty elaborating on plans of
actions for future behavior and are linked to lesions in the dorsolateral prefrontal cortex and the
dorsal caudate nucleus of the basal ganglia. The deficit in auto-activation is the inability to selfinitiate thoughts and actions with spared ability to generate externally motivated behavior and is
known as the most severe aspect of apathy (Levy & Dubois, 2006). Deficits in auto-activation
are seen when bilateral lesions in the limbic system, particularly the globus pallidus, result in
diminished signal to the frontal cortex. While apathy is well-defined, researched, and correlated
with structural brain regions, a potential source of confusion presents when one attempts to
distinguish apathy from depression, given their similar clinical presentations.
1.8 Distinction between Apathy and Depression
According to the Diagnostic and Statistical Manual of Mental Health Disorders (DSM-5),
depressive disorders are defined by the presence of sad mood and significant cognitive and
somatic changes that cause functional impairment. The World Health Organization defines
depression as a syndrome with permanent abnormal mood for at least two consecutive weeks and
a marked diminished interest or pleasure and decreased energy associated with at least one of the
following: loss of confidence, excessive guilt, recurrent thoughts of death, poor concentration,
sleep disturbance, and change in appetite/weight. Apathy is not a clinical criterion for depression,
but it is often present in individuals with depression (Marin et al., 1993). While apathy and
depression both affect similar target areas in the brain, apathy is known to occur in the absence
of depression, such as MCI, AD, and PD, rather than from altered affect and correlates with
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distinct locations of lesions in the brain (Anderson et al., 1999). Overall, apathy and depression
may coexist, but they are also clinically independent syndromes.
When apathy occurs in the context of depression, it is best described as decreased
motivation and difficulty initiating thoughts, emotions, and goal-directed behavior, which is
associated with disruptions in the frontal-striatal circuitry of the brain (Marin, 1990). Depression
is characterized by dysphoric symptoms (e.g., sadness, guilt, and helplessness) not seen in
individuals with apathy alone. Depressed individuals also have high rates of negative selfcriticism. In contrast, apathy is characterized by a lack of emotional responses and a lack of
concern in general (Marin, 1990; Marin, 1997). Both depression and apathy can lead to loss of
interest, but the underlying etiology is different. In depression, loss of interest is due to feelings
of despair, pessimism, and hopelessness. In apathy, loss of interest is due to decreased
motivation (Marin, 1997). The theory of separate constructs is further supported based on
treatment differences: depression is treated with SSRIs while apathy is not, as SSRIs can
exacerbate apathy, particularly in older adults (Wongpakaran et al., 2006).
Often, apathy occurs as a symptom of depression, but true apathy and depression are
clinically independent from one another, which is why emotional blunting in individuals who
adequately respond to SSRI treatment can still occur (Levy & Czernecki, 2006). While apathy
and depression share many overlapping symptoms like blunted affect, lowered initiation of goaldirected behaviors, and a lack of engagement, many symptoms of depression are exclusive to
depression alone such as suicidal ideation, crying, changes in sleep, and hopelessness (Marin,
1990; Landes et al., 2001).
Pure apathy is a commonly seen neuropsychiatric symptom of many neurological
diseases, which is further evidence that apathy is an independent construct and occurs in the
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absence of depression. For example, many patients with progressive supranuclear palsy (PSP)
and frontotemporal dementia (FTD) rarely meet criteria for depression but often present with
apathy (Marin et al., 1994; Yeager & Hyer, 2008). Forty percent of patients with MCI and AD
also exhibit apathy whereas only twenty percent of patients with MCI or AD exhibit depression
(Apostolova & Cummings, 2008). Similarly, meta-analyses show that apathy occurs in
approximately 40% of all Parkinson’s disease patients (den Brok et al., 2015). Like FTD and
PSP, Parkinson’s disease-related apathy likely occurs secondary to disruptions in the frontalsubcortical circuitry (den Brok et al., 2015). Some studies have attempted to clarify the
differences in frontal circuitry deficits via neuropsychological evaluation. For example, a 2012
study of 90 patients revealed that depression alone was associated with poor set-shifting. This
study also revealed that apathy, not depression, was associated with increased functional
impairment (Zahodne & Tremont, 2012). Similarly, research looking at cognitive impairment in
Alzheimer’s disease showed that self-report measures of apathy and depression often correlate
due to overlapping symptoms of loss of interest, psychomotor slowing, and a lack of energy
(Marin et al., 1993); therefore, separate scales to address apathy independently were created.
Currently, psychometric support exists for the use of self-report scales that measure apathy
independently, with validated questionnaires and well-established cut-off scores (Marin, 1991).
Multiple scales also exist to assess apathy as a distinct clinical presentation (Radakovic &
Abrahams, 2014; Robert et al., 2002; Sockeel, 2006).
The measurement of apathy as a separate construct began in the 1990s for neurological
populations, though the first self-report questionnaire for SSRI-induced apathy was created 20
years later (Price et al., 2012). The Questionnaire on the Emotional Side-effects of
Antidepressants (OQuESA; Price et al., 2012) specifically targets the emotional components of
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apathy like blunted affect and poor social engagement, with an index to determine how much
people believe that the SSRI is responsible for their current state. With apathy and depression
viewed as distinct and separate constructs, SSRI-induced emotional blunting in treatment
responders (i.e., those who no longer feel depressed) should be assessed in the absence of
depression. The current study seeks to look at new onset emotional blunting via the OQuESA
after long-term SSRI use to ensure that changes in emotional processing are exclusively due to
SSRI-induced changes and not to lingering symptoms of depression.
While apathy in depression may look similar to SSRI-induced emotional blunting, true
emotional blunting only occurs after SSRI administration and would not be seen in a depressed
patient not on medication (Plowden, 2019). This unique difference in timing allows prescribers
to better distinguish between depression and a new onset apathy syndrome. Many individuals
who have SSRI-induced apathy will initially get better, as the SSRI is effective in treating the
depression, but later deteriorate due to the side effect of apathy (Plowden, 2019). Given the
overlap in symptoms of depression and new onset blunting, this study will look only at treatment
responders who no longer endorse depressive symptoms. It would be nearly impossible to
determine if changes in cognition and behavior were due to depression or SSRI-induced apathy
prior to successful recovery from depression. By eliminating individuals with continued
depressive symptoms and only looking at non-depressed treatment responders, this study will be
able to draw conclusions about pure SSRI-induced apathy without having to consider
confounding overlap with lingering depression. The impact of SSRI-induced apathy on
processing emotional information will be able to be examined, similar to the way past research
has looked at the effect of neurological disease-induced apathy on cognition.
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1.9 Social Support and Mental Health
In recent decades, many studies have cited the importance of social support and close
relationships in individuals with mental illness. Social support involves positive interactions
between people who are perceived as helpful and provide psychological advantages (Harandi et
al., 2017). Social support is known to improve quality of life, aid with mental illness, and be
protective from the effects of stress (Turner & Brown, 2010). Social support is also seen as one
of the top three most important constructs in mental health research (Veiel & Baumann, 2016).
Lack of perceived social support is directly related to depressive symptoms, especially later in
life (Berkman & Glass, 2000). More recent research shows that the relationship between social
support and depression is strong, as social support can aid in recovery after depression has
already occurred, especially for women and older adults (Harandi et al., 2017; Grey et al., 2020).
Beyond depression, social support is inversely related to anxiety, loneliness, irritability, and poor
sleep quality (Grey et al., 2020; Roohafza et al., 2014). With decades of research highlighting
the importance of social support in the prevention and recovery of mental illness, ensuring that
treatments, such as SSRIs, do not perpetuate social distance or increase the risk of individuals
withdrawing from their social networks due to emotional blunting is essential. Social support is
an integral protective factor against mental illness that prescribers need to ensure is not altered or
damaged by SSRI-induced emotional blunting.
1.10 Neurological Biomarkers of Blunting
Initial anecdotal reports of emotional blunting from SSRI-users prompted fMRI research
to capture SSRIs’ effects on the brain, as neuroimaging biomarkers of emotional blunting could
help better predict treatment response, in turn, helping clinicians implement changes in treatment
for better patient outcomes (Spies e al., 2017). Techniques, such as fMRI, have helped
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researchers determine differences in brain activity based on the amount of oxygen use in specific
brain regions. Functional magnetic resonance imaging is an expensive and time-consuming
procedure, though it could hypothetically allow prescribers to see activation changes of emotion
regulating areas, aiding in the assessment of emotional blunting. For example, if a brain region
uses a steady and high amount of oxygen from the blood, that region becomes highly activated.
One study assessed the emotional discrimination abilities of patients with Major Depressive
Disorder (MDD), examining their brain activity prior to SSRI treatment and then, again, after
two and four weeks of SSRI escitalopram (Lexapro) administration. Overall, deactivation of the
precuneus and posterior cingulate cortex, areas known for processing and detecting negative
information, resulted in lower levels of depression after two weeks of treatment (Spies et al.,
2017). Similarly, a study of patients with MDD showed deficits in managing cognitive
interference when distractors had negative emotional valence (Fales et al., 2009), suggesting that
people with depression are drawn to negatively charged information. When compared to MDD
patients without SSRI treatment, SSRI-users had a significant increase in activation of the
dorsolateral prefrontal cortex (DLPFC), above and beyond the depressed group not on SSRIs.
They also showed a reduction of amygdala activity in response to photos of fearful facial
expressions (Fales et al., 2009). These results suggest that antidepressant therapy may actually
improve recruitment of the DLPFC during performance of emotional interference tasks, thus
leveling out the negative bias often seen in depression.
Some studies have even tested SSRI use independent of depression by putting healthy
control subjects on an SSRI to truly distinguish emotional blunting that is merely induced by an
SSRI and not part of the originally-treated condition of depression. McCabe and colleagues
(2010) assessed neural responses to rewarding (pleasant sight and/or flavor) and aversive stimuli
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(unpleasant sight and/or flavor) after one week of SSRI citalopram (Celexa) treatment. Results
showed that citalopram reduced activation to the pleasant stimuli in the ventral striatum and the
ventral medial/orbitofrontal cortex. Furthermore, citalopram also decreased neural responses to
aversive stimuli in key “punishment” brain areas such as the lateral orbitofrontal cortex. Thus,
SSRI treatment decreases neural processing of both rewarding and aversive stimuli, which can be
problematic if a person is also experiencing SSRI-induced decreased motivation and anhedonia
(McCabe et al., 2010). A comparable randomized control trial of depressed patients using
citalopram or reboxetine (norepinephrine reuptake inhibitor-NaRI) found that, overall, these
antidepressants decreased the recognition of negative emotions (Tranter et al., 2009).
While Tranter and colleagues (2009) found that both norepinephrine and serotonin
affected emotional recognition, other studies looking at dopaminergic and serotonergic
manipulation indicated that healthy controls had altered neural emotional responses to unpleasant
pictures when given an SSRI or D2 antagonist (Takahashi et al., 2005). Functional magnetic
resonance imaging (fMRI) revealed that acute administration of a therapeutic dose of dopamine
(DA) D2 antagonists and fluvoxamine (Luvox-SSRI) had modulatory effects on emotional
processing. Specifically, the amygdaloid-hippocampal regions, orbitofrontal cortex, basal
ganglia, and insula showed reduced activation when subjects viewed unpleasant images
(Takahashi et al., 2005). Unlike the DA D2 antagonist, SSRI treatment produced greater
activation only in the temporal cortex and parietal cortex, and not in the frontal cortex,
suggesting that SSRI use may primarily affect the frontal lobe, which is known to be related to
emotional processing and personality (Takahashi et al., 2005). Although both DA D2 antagonist
and SSRI treatment resulted in common inhibitory effects on amygdaloid – hippocampal regions,
the different patterns found in the prefrontal cortex strongly confirm that SSRI use uniquely
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affects the brain. This pattern of inhibition on prefrontal cortex occurred even when subjective
ratings of affective pictures did not produce a significant difference between groups, confirming
that self-report of emotion is indeed unreliable and uncorrelated to biological changes such as
neuronal activation (Takahashi et al., 2005). Acute administration of SSRIs reduced activity in
the amygdala, suggesting the brain’s primary emotion center was being down-regulated or
“blunted.” In addition, SSRI use did not raise activity in the frontal cortex, which is a region
likely requisite for full emotional processing of information. It is known that depression causes
hypoactivity in left frontal areas and hyperactivity in right frontal areas (Walsh et al., 2010);
therefore, changes in frontal lobe processing would be expected to alter with SSRI usage to
combat depression.
While most of the aforementioned work assessed differences between SSRIs and other
drugs in healthy controls, functional neuroimaging emotion research has also been done to assess
whether neural markers of early emotional processing changes predict later clinical response in
depression (Godlewska et al., 2016). At baseline, depressed patients showed greater activation to
fearful faces versus happy faces than controls in the insula and dorsal anterior cingulate.
Furthermore, “treatment responders” had a greater reduction in neural activity to fearful versus
happy facial expressions in a multitude of brain regions including the anterior cingulate, insula,
amygdala, and thalamus, suggesting that these areas were no longer hyperactivated by negative
emotional information. Overall, these longitudinal results support the hypothesis that changes in
emotional processing occur early on in antidepressant usage (Godlewska et al., 2016) and
parallel Fales’ (2009) findings of changes in emotional processing after only two weeks of SSRI
administration.
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Beyond looking at specific regions of the brain, research has examined broader
hemispheric differences during processing of emotional information. Walsh and colleagues
(2010) assessed SSRI-users that ranged from never depressed, previously depressed, and
currently depressed/using SSRIs (including “responders” whose depression improved post SSRI
versus treatment resistant “non-responders”). Each group viewed both positively- and
negatively-valenced words to determine if SSRI use caused hemispheric differences in
activation. SSRI responders and never-depressed participants were similar in their left
hemispheric lateralization when evaluating emotional words. On the other hand, SSRI nonresponders showed a relative shift towards right hemisphere processing of negative words and a
strong bias toward negative evaluation of words in the right hemisphere. In sum, patients still
having symptoms of depression had different hemispheric activation than patients who
responded well to the SSRI. It is possible that non-responders to SSRI administration experience
emotional blunting, which prevents them from feeling better, contrasting with the notion that
non-responders are truly treatment-resistant. The current work seeks to examine only SSRI
treatment responders in order to distinctly study SSRI-induced emotional blunting without
persistent depressive symptoms. Non-responders were omitted because they leave too much open
to interpretation, as SSRI-induced emotional blunting has substantial overlap with depressive
apathy.
1.11 SSRI Research in Anxiety Disorders
While SSRIs are primarily used to treat MDD, they have also been clinically indicated in
anxiety disorders, such as panic disorder, social phobia, post-traumatic stress disorder,
generalized anxiety disorder, and obsessive–compulsive disorder. These disorders do not have
the same rate of anhedonia and apathy as MDD; therefore, examining SSRI use in these
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populations allows researchers to view anhedonia and SSRI-induced emotional blunting as two
separate and distinct constructs (Burghardt and Bauer, 2013). To investigate the effects of SSRIs
in the brain, Burghardt and Bauer measured behavioral effects in animals subjected to Pavlovian
fear conditioning. To demonstrate how SSRIs affect the functioning of specific brain regions,
including the amygdala, nucleus bed of the stria terminalis, and hippocampus during fear,
Burghardt and Bauer (2013) acutely administered an SSRI. Neural activity in the extended
amygdala and hippocampus showed enhanced activation from cued fear conditioning. This effect
additionally impaired context-dependent fear conditioning (Burghardt & Bauer, 2013).
Furthermore, the effects of chronic SSRI treatment on fear conditioning in rodents revealed that
down regulation of N-methyl-D-aspartate (NMDA) receptors in the amygdala and hippocampus
may mediate impairments in fear learning and memory (Burghardt & Bauer, 2013). These results
suggest that long-term SSRI use in humans potentially causes differences in cognitive processing
of fear and other emotions.
1.12 Cognitive Effects of Depression
To date, many studies have highlighted the cognitive changes associated with
pathophysiology, symptoms, and treatment of depression. Cognitive symptoms of major
depressive disorder include abnormal emotion processing and altered cognitive function,
including executive dysfunction, which can be seen on fMRI (Fales et al., 2009). In terms of
emotional processing specifically, depression is associated with a wide scope of negative biases.
For example, depressed individuals are more likely to selectively recall negative, self-related
emotional information in memory tasks and demonstrate negative biases in the perception of
social signals such as emotional facial expressions (Godlewska et al., 2016). Hypoactivity in left
frontal and right posterior areas and hyperactivity in right frontal areas are also linked to
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depression. Vulnerability to depression is linked to specific neurophysiological characteristics,
including greater right-hemisphere (RH) relative to left-hemisphere (LH) activity. This atypical
pattern of hemispheric asymmetry seems to be a stable trait present in both those at risk for and
those in remission from depression (Walsh et al., 2010). Past work in depressed samples also
recorded altered recognition of facial expressions, likely due to underlying cognitive changes and
increased sensitivity to subtle social cues (Harkness et al., 2005; Persad & Polivy, 1993). One
study on SSRI use and emotional processing showed that sub-chronic SSRI exposure decreased
accuracy of facial expression recognition (Harmer et al., 2004). Depression is also associated
with executive dysfunction especially in domains of psychomotor speeds and inhibition when
compared to their non-depressed counterparts (Bennabi et al., 2013; Channon & Green, 1999).
While most research has focused on changes in the amygdala and prefrontal cortex,
neurobiological models of depression also emphasize alterations in language centers (Merens et
al., 2007). For example, some studies have discovered that depressed individuals demonstrate
reduced semantic fluency (Fossati et al., 2003; Schmid & Hammer, 2013).
To gauge the depth and breadth of depression on cognition, some researchers use a
method of tryptophan depletion which is thought to decrease neuronal serotonin to mimic the
“depressed brain” (Neumeister, 2003). Tryptophan depletion reveals slowed responses to
positive verbal stimuli in an affective go-no go task (Murphy et al., 2002), reduced memory for
positive affective information (Klaassen et al., 2002), and increased Stroop interference for
negative stimuli (Evers et al., 2006). These effects perpetuate a negative skew on a cognitive
level and may be similar to an SSRI blunted brain, as depression apathy and SSRI-induced
blunting have such a high level of overlap.
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With cognitive changes in depression well documented, it is crucial to switch gears and
begin looking at cognitive changes in patients who not only take SSRIs, but also report
emotional blunting associated with their prescription use. Research on cognitive changes in
depression proves fMRI’s ability to elucidate changes in emotional processing, but fMRI is not
typically used in clinical practice. At present, insurance companies do not cover the cost of fMRI
to establish cognitive changes secondary to depression. This type of testing is expensive and
cumbersome, placing a high burden on the patient. Without the use of fMRI in depressed
patients, there is little hope that such a test would be offered to SSRI-users who report emotional
blunting; therefore, finding alternative ways to assess emotional processing and cognitive
changes associated with SSRI use is warranted.
1.13 Past Research in Emotional Processing with SSRI Use
Limited research exists on the direct link between cognitive processing of emotionally
charged information and SSRI use. Though limited, research has shown that SSRI use does
indeed alter the way the brain processes emotional information, but these studies largely focus on
acute SSRI administration (Fales et al., 2009; Godlewska et al., 2016). One study found that
healthy subjects on citalopram (an SSRI) for one week had a reduced ability to identify facial
expressions of anger and fear when compared to their placebo counterparts (Harmer et al., 2004).
Likewise, one week of citalopram resulted in decreased startle response for negative affective
images.
Beyond short-term SSRI use, little research has assessed altered processing of emotional
information in chronic SSRI use for depression. One study on SSRI use and emotional
processing showed that sub-chronic SSRI exposure decreased accuracy of facial expression
recognition (Harmer et al., 2004). Past work in depressed samples recorded altered recognition of
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facial expressions, likely due to underlying cognitive changes and increased sensitivity to subtle
social cues (Harkness et al., 2005; Persad & Polivy, 1993), which may be similar to the effects
on SSRI-users with emotional blunting given the overlap in clinical presentation.
Along with facial recognition accuracy, there is longstanding literature that supports a
phenomenon known as “emotional interference.” Emotional interference is characterized by
attentional changes when individuals are presented emotional stimuli that resonate closely with a
person. For example, individuals with PTSD often show slowed reaction times when presented
with words closely associated with their trauma (Vythilingam et al., 2007). Comparably, multiple
studies demonstrate that depressed patients have slower response times to negatively valenced
words than to positive or neutral words, above and beyond their control counterparts
(Mitterschiffthaler et al., 2008; Ros et al., 2021). Hence, emotional interference appears to be
related to the thematic relevance of the personally experienced event. Since SSRI-induced
emotional blunting results in a distance from all emotions and is associated with pulling away
from loved ones and difficulty with social interactions (Garland & Baerg, 2001), these
individuals may “pull away” and distance themselves from all emotionally charged information,
resulting in changes in processing speed. While these studies addressed differences in emotional
processing associated with psychopathology, little research on emotional processing changes
stemming from SSRIs exists.
1.14 The Current Study
This study seeks to build upon past research by investigating emotional processing
changes in long-term SSRI-users to determine if SSRI-users who specifically report varying
levels of emotional blunting and/or sexual dysfunction demonstrate differences in emotional
processing than long-term SSRI-users without these difficulties. By focusing on cognitive
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changes, the current study attempts to find an objective way to quantify emotional blunting. If
SSRI-induced emotional blunting alters cognitive performance on tasks that contain emotionally
charged information, prescribers could rely on differences in cognitive performance over time to
objectively capture blunting without needing to rely on a patient’s awareness and ability to detect
its presence. Assessing emotional blunting by measuring cognitive changes would also allow for
preventative care instead of waiting for the side effect of emotional blunting to emerge. This
study would be the first of its kind, assessing the effects of emotional blunting beyond anecdotal
report and considering that emotional blunting can also alter emotional processing in patients on
SSRIs. This information would foster a more in-depth understanding of how SSRI-induced
blunting impacts emotional processing and the social implications this change can have on a
person’s life.
This study also seeks to fill gaps in the current literature by examining long-term SSRIusers. Previous work on emotional blunting, including fMRI studies, has tested SSRI effects in
healthy volunteers who receive an SSRI only once or for a brief period of time (minutes or
weeks rather than the typical months or years of treatment). The novel approach used here of
studying SSRI-users who have been on medication for at least two months to treat depression is
more applicable to real-world cases, as SSRIs are only prescribed for a psychiatric condition and
not to healthy individuals. Furthermore, this study seeks to study the relationship between
emotional blunting and sexual dysfunction given that sexual dysfunction is one of the most
common and pressing side effects of SSRI use. One study noted the correlation between SSRIinduced sexual dysfunction and emotional blunting (Opbroek et al., 2002), but, to date, there is
limited research, and the correlation has only been established based on case study. An
experimental design that allows for the evaluation of cognitive differences in long-term SSRI-
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users with and without emotional blunting and with and without sexual dysfunction will allow
for generalizability of findings, provide a potential avenue for detection of this insidious side
effect, and build on the limited empirical work addressing SSRI-induced emotional blunting.
1.15 Current Aims and Hypotheses
This study aimed to investigate the effects of long-term SSRI use on emotional processing of
information in treatment responders. The present study has the following aims:
Aim 1. To determine if long-term SSRI-users show differences in their cognition when
processing emotional information.
Hypothesis 1A. I expected that long-term SSRI-users would have lower accuracy in
recognizing emotions than controls, as determined by the Affect Naming task.
Hypothesis 1B. I predicted that long-term SSRI-users would show smaller differences in
reaction times based on valence of words (positive, neutral, and negative) than controls, as they
are more likely to feel blunted and feel distanced from all emotions. I hypothesized that there
would be greater differences between reaction time for positive and neutral words or negative
and neutral words in control subjects when compared to SSRI-users, as they may feel more
aligned with emotional content. This will be determined by their reaction times on the Emotional
Stroop Task.
Aim 2. To determine if long-term SSRI-users who endorse emotional blunting (as determined by
the OQUeSA) show greater differences in cognitive processing of emotional information than
long-term SSRI-users who do not endorse emotional blunting.
Hypothesis 2A: I hypothesized that long-term SSRI-users who report emotional blunting
would have poorer accuracy in recognizing emotions than long-term SSRI-users who
subjectively deny emotional blunting, as determined by the Affect Naming task.
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Hypothesis 2B: I hypothesized that long-term SSRI-users who subjectively endorse
emotional blunting would show less variability in reaction times based on emotional valence of
words (positive, neutral, and negative) than long-term SSRI-users who do not report emotional
blunting, as they are more likely to feel blunted and feel distanced from all emotions. This will
be determined by their reaction times on the Emotional Stroop Task.
Aim 3. To determine if SSRI-users who attribute their blunting specifically to their
antidepressant process emotional information differently.
Hypothesis 3A. I hypothesized that long-term SSRI-users who attribute their blunting to
their antidepressant would have poorer accuracy on recognizing facial expressions than longterm SSRI-users who do not attribute their blunting to SSRI use, as determined by the Affect
Naming task.
Hypothesis 3B. I hypothesized that long-term SSRI-users who attribute their blunting to
their antidepressant would show less variability in reaction time based on emotional valence of
words (positive, neutral, and negative) than long-term SSRI-users who do not attribute their
blunting to SSRI use. This will be determined by their reaction times on the Emotional Stroop
Task.
Aim 4. To determine if long-term SSRI-users who report sexual dysfunction as a side effect are
more likely to experience emotional blunting.
Hypothesis 4A: I hypothesized that long-term SSRI-users who endorse sexual dysfunction
(low libido and/or difficultly/inability to orgasm) would have higher levels of emotional blunting
than long-term SSRI-users who do not endorse any sexual dysfunction side effects, as
determined by the OQUeSA.
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Aim 5. To determine whether long-term SSRI-users who endorse sexual dysfunction are at an
increased risk of inaccurately processing emotional information.
Hypothesis 5A: I hypothesized that SSRI-users who report sexual dysfunction side effects
(low libido and/or difficulty/inability to orgasm) would have poorer accuracy in recognizing
emotions than long-term SSRI-users who do not report sexual dysfunction side effects due to
higher levels of emotional blunting, as determine by the Affect Naming task.
Hypothesis 5B: I hypothesized that long-term SSRI-users who subjectively endorse
sexual dysfunction would show less variability in reaction times based on valence of words
(positive, neutral, and negative) than long-term SSRI-users who do not report sexual dysfunction
due to higher levels of emotional blunting. This will be determined by their reaction times on the
Emotional Stroop Task.
2. Methods
2.1 Study Design
Power Analysis
Power analysis was conducted using G*Power (Faul et al., 2007). Estimation of sample
size was based on a general linear model with between subject factors. The effect size for the
main outcome measures in this sample was expected to be small to medium, based on the
relatively low level of psychiatric severity and cognitive difficulties expected to be detected in
the sample. Based on this power analysis, a sample size of 64 participants per group was
adequate to detect a small to medium effect size with 0.80 power at the .05 level of significance
for the primary outcome measures.
Recruitment
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This study was approved by the Institutional Review Board of Queens College, CUNY.
Participants were recruited via Prolific, an online research platform that has a built-in database of
registered SSRI-users. Participants were required to be at least 18 years old, live in the United
States, have access to a computer, and have English proficiency. Mobile viewing of the survey
was disabled in order to standardize administration of the Emotional Stroop Task. For SSRIusers, individuals were required to be on the medication for a minimum of two months, to
establish what I defined as “long-term use.” Participants were excluded if they reported using
any psychiatric medication other than an SSRI, such as benzodiazepines, serotoninnorepinephrine reuptake inhibitors (SNRIs), or antipsychotic medication. Due to the overlap in
symptoms between SSRI-induced emotional blunting and depression-induced apathy,
participants who met criteria for depression (BDI-II > 13) were excluded from the main results in
order to determine if the effects were truly from new onset blunting. Individuals who met criteria
for anxiety (BAI > 15) were also excluded due to an exceptionally high comorbidity rate (~50%)
between anxiety disorders and depressive disorders and because individuals with anxiety are
known to have altered emotional processing (Brown et al., 2001). Individuals who endorsed
color blindness were also excluded, as they would not be able to participate in the Emotional
Stroop Task. Participants were compensated $2.85 for their participation. Participants consented
online and confirmed they were a human using reCAPTCHA. They then completed the Beck
Depression Inventory, the Beck Anxiety Inventory, a demographics survey, and the OQuESA.
Individuals on SSRIs, a category that was preselected on Prolific, also filled out the SSRI usage
form. Following self-report measures, all participants completed the Emotional Stroop Task and
viewed the Advanced Clinical Solutions Affect Naming task. Two attention check questions
were included in the survey.
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2.2 Participants
Two hundred and twenty-seven participants (118 SSRI-users and 109 control subjects)
participated online. Of those 227 subjects, 105 scored above the cut off for depression (BDI-II >
13) and were omitted from the reported analyses. While this rate of depression (almost 50%) is
far higher than national averages, data were collected in October of 2020 during the COVID
pandemic which may partially explain general mental health during this time. Thus, the
following analyses are based only on the 122 adults who screened as non-depressed.
Final Sample
In the final sample of 122 adults, 50% (n=61) reported current SSRI use and 50% (n=61)
were controls (see Table 1). Overall, the sample mean age was 35.18 years (SD = 13.48). Most
participants were white (77.0%, n=94), 9.8% were Asian (n= 12), 7.4% were African American
(n= 9), 2.5% were American Indian/Native Alaskan (n= 2), and 4.1% identified as ‘other’ (n= 5).
The majority of participants were heterosexual (81.15%, n=99), with 6.55% identifying as gay
(n= 8), 8.2% identifying as bisexual (n= 10), and 4.1% identifying as ‘other’ (n= 5). Seventyeight people (63.9%) reported being in a romantic relationship. Most reported a household
income of $30,000 or less (21.3%, n= 26), with 15.25% stating their annual household income as
$30,000-$50,000 (n= 19), 18.85% in the $50,000-$70,000 range (n= 23), 13.95% in the $70,000$90,000 range (n= 17), 14.75% in the $90,000-$125,000 range (n= 18), 11.5% in the $125,000$175,000 range (n= 14), and 4.1% in the $175,000 and greater range (n= 5).
Among the SSRI-users, the average number of months of antidepressant use was 71.26
(SD=3.83). Chi-square tests of independence and ANOVAs were conducted to determine
demographic group differences between controls and SSRI-users. Significant between-group
differences included SSRI user participants being disproportionately female (62.3% vs. 37.7% of
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controls), white (86.9% vs. 67.2% of controls), and older (mean age of 38.26 years vs. 32.10
years in controls). More SSRI user participants also reported being gay (11.5%) or bisexual
(13.1%) than control participants (1.6% and 3.3%, respectively). No other significant differences
were observed (see Table 1).
2.3 Measures and Materials (see descriptive statistics in Table 9)
SSRI Usage Form. This 5-item self-report measure was developed by the lab to inquire about
length, dosage, and brand of SSRI. Sample items include “What brand is your SSRI?” and “What
dosage in milligrams do you currently take daily?” Participants also listed any side effects they
currently attributed to their SSRI usage. Sample side effects include low libido, weight gain,
nausea, difficulty reaching orgasm, or “other.”
Beck Depression Inventory. The Beck Depression Inventory (BDI-II; Beck et al., 1996) is a
21-item, self-rated scale that evaluates for clinical depression within the past two weeks.
Questions in the measure tap into symptoms of depression, such as suicidal ideation, crying,
indecisiveness, loss of libido, guilt, crying, self-dislike, changes in sleep and appetite, irritability,
fatigue, sense of failure, and overall mood. Using both cognitive and somatic symptoms of
depression, the BDI-II has high test-retest reliability (Pearson r= 0.93) and had high internal
consistency in this study (α= 0.94). Each symptom assessed on the measure is ranked in terms of
severity on a four-point scale, from a 0 (not at all) to 3 (severely- ‘I could barely stand it’). A
total score is then generated by summing the severity ratings for all 21 items.
Beck Anxiety Inventory. The Beck Anxiety Inventory (BAI; Beck et al., 1988) measures
clinical anxiety. This 21-item scale evaluates clinical anxiety within the past month. Questions in
the measure tap into symptoms of anxiety, such as feeling nervous, fearing death, trembling,
heart pounding, and feeling scared. Each symptom is ranked in terms of severity on a four-point
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scale, from 0 (not at all) to 3 (severe). Using both cognitive and somatic symptoms of anxiety,
the BAI had high internal consistency for this study (α= .95).
Oxford Questionnaire on the Emotional Side-effects of Antidepressants. The Oxford
Questionnaire on the Emotional Side-effects of Antidepressants (OQUeSA; Price et al., 2012) is
a 26-item measure of restricted emotions that contains a subsection focused on SSRI use. This
questionnaire focuses on four factors of emotion restriction experienced during the past week
that can be attributed to SSRI use: ‘not caring’, ‘emotional detachment’, ‘general reduction in
emotions’, and ‘reduction in positive emotions.’ Participants rated their emotionality ranging
from 1 (disagree) to 5 (agree). Sample items include “my emotions lack intensity,” “I don’t care
as much about my day-to-day responsibilities as I did before I developed depression,” and “the
antidepressant is preventing me from feeling positive emotions.” A total score is calculated by
summing totals from the four aforementioned subscales. The overall internal consistency
reliability (Cronbach’s alpha) for this study was .95. Subscale reliability was also high for
general reduction in emotions (α=.814), reduction in positive emotions (α=.89), emotional
detachment from others (α=.86), and not caring (α=.86). Additionally, the ‘antidepressant as
cause’ subscale was also highly reliable (α=.92).
Demographic Questionnaire. A demographic questionnaire assessed age, sex, race, ethnicity,
household incomes, relationship status, sexual orientation, and psychotropic prescription
medication use.
Affect Naming Task. The Affect Naming task is a subtest of the Wechsler Advanced Clinical
Solutions test of Social Cognition (Pearson, 2009). This task consists of 24 pictures of
individuals expressing different facial expressions (i.e., happy, sad, neutral/no feeling, angry,
surprised, disgusted, and afraid). Test-takers are asked to choose the correct emotion being
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expressed by each picture. Items are scored as a 1 for correct and a 0 for incorrect responses. A
total accuracy score is generated by adding up all 24 trials. The internal consistency of this
measure was .57 for this study.
Emotional Stroop Task. This color-word task was adapted from the traditional Stroop test
in which participants must name colors as fast as they can, read words as fast as they can, and
then name the color that words are printed in (inhibit the tendency to read the word) to measure
processing speed via reaction time. In the current version, participants were shown 96 words that
flashed on the screen in blue, red, green, or yellow ink. The words provided were a mix of 32
neutral, 32 positive, and 32 negative words, such as ‘margin,’ ‘prize,’ and ‘victim.’ These words
were compiled from stimulus sets employed in previous studies (Becker et al., 2001; Kitayama &
Ishii, 2002; Miller & Patrick, 2000; Paunovic et al., 2002) and were matched for length and
frequency of use across groups. In the adapted version, participants were asked to correctly and
quickly choose the color of the ink that randomly flashed words were displayed. For example,
participants saw the word “label” printed in green and four color choices below the word (i.e.,
red, yellow, green, and blue). For this example, participants would choose “green.” After 10
practice trials, participants viewed 96 words (32 positive words, 32 neutral words, and 32
negative words) in varying colors. Of note, each participant’s word order was randomized to
reduce order effects. Subjects were told to respond to the color of the ink for each word and
identify this color as quickly as possible by hitting the corresponding key on their computer.
Reaction time was assessed and compared between emotionally-valenced word groups. Internal
consistency for response times were as follows: neutral words (α= .88), positive words (α = .68),
negative words (α= .69).
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This task was chosen specifically as a measure of executive functioning and processing
speed given the emotional content utilized, as past research has shown that serotonin, the primary
neurotransmitter being modulated by SSRIs, affects performance on emotionally salient rewards
and feedback (Chamberlain et al., 2006). Beyond emotional processing changes, research
demonstrates that SSRI use can actually boost other areas of cognition, if it is able to ameliorate
the symptoms of depression, rather than cause impairments (Constant et al., 2005; HerreraGuzman et al., 2010). One study found that acute administration of SSRIs in both control
subjects and patients with MDD improved working memory, attention, and executive
functioning in both groups (Cassano et al., 2002; Herrera-Guzman et al., 2010) while other
studies have documented improved psychomotor speed in patients with MDD (Constant et al.,
2005). With this knowledge, it was essential to pick a test that was sensitive to changes in
processing of emotional information, as SSRI-induced emotional blunting is only known to
disrupt emotional responding and was the area predicted to be impacted by SSRI-induced
emotional blunting. Given the need to address emotional cognition particularly, the utilization of
the Emotional Stroop task allowed for pure reaction time, as measured by neutral words, and
reaction time with emotional information, as measured by positive and negative words. This task,
above others, allowed for comparisons of reaction time in emotional and non-emotional stimuli,
which was advantageous and meaningful.
2.4 Pandemic Effects on Study Design
With the onset of the COVID-19 pandemic, there was a civil duty to stop all in-person
research to help efforts to stave off the virus. This also became a necessity once CUNY
disseminated guidelines to discontinue all in-person research. Thus, several changes were made
to this study. Initially, this project (n=11) included assessment of the physiological effects of
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SSRI-induced emotional blunting (i.e., respiration rate, skin conductance, and heart rate) which
were to be taken after participants viewed emotionally-charged videos (i.e., positive, neutral, and
negative). I originally hypothesized that the SSRI-users with emotional blunting would show less
physiological change between different emotional valences than both the control group and the
SSRI-users who did not report emotional blunting. It was also predicted that SSRI-users who
reported sexual dysfunction would show a similar physiological pattern to those reporting
emotional blunting. The COVID-19 pandemic forced revisions to change the protocol to a fully
remote format, such that physiological measures were no longer tenable. An IRB amendment
was submitted in July of 2020 to change the study to a remote online survey format. Dependent
variables were thus limited to the Affect Recognition and Emotional Stroop tasks.
3. Statistical Analyses
3.1 Data Entry
All analyses were performed using the IBM Statistical Package for the Social Sciences
(SPSS) version 27. The primary independent variable for group was coded for SSRI status
(0=controls/no SSRI use vs. 1=current long-term SSRI use). For secondary analyses, two
variables were used as potential characteristics of emotional blunting. The first was current
sexual dysfunction based on endorsement of either decreased sexual desire and/or anorgasmia
(0=no, 1=yes). The second measure of emotional blunting was perceived level of “antidepressant
as the cause” (0=low, 1=high). Dependent variables (OQUeSA total and subscale scores, Affect
Naming task scores, and Emotional Stroop task scores) were entered as continuous variables,
including total scores for Affect Naming accuracy and mean response times for each of the
Stroop emotional word valence conditions (neutral, positive, negative). To assess moderation, an
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interaction term was created by multiplying group status (controls versus SSRI-users) with
emotional blunting as measured by OQUeSA centered total score.
3.2 Data Analyses
Means and standard deviations were computed to describe continuous variables, while
frequencies and percentages were used for categorical variables. All statistical tests were twotailed and performed at = 0.05 for interpretation. The chi-square test for independence (Fisher’s
Exact Test) was used to evaluate between-group differences for the demographic characteristics
of sex, race, sexual orientation, current romantic relationship, and annual household income.
One-way analysis of variance (ANOVA) tests were used to evaluate baseline differences in age,
depression, and anxiety. General linear models were used to determine between-group and
within-subject mean differences in scores on the OQUeSA and responses to the Affect Naming
and Emotional Stroop tasks. Moderation analysis, as outlined Hayes and Rockwood (2013) using
the PROCESS macro for SPSS v.27, was conducted to determine whether main effects of the
independent variable (group) on outcome variables (Affect Naming and Emotional Stroop tasks)
were affected by the hypothesized moderating variable (emotional blunting as measured by the
OQUeSA). Ordinary Least Squares (OLS) regression was conducted through Model 1 in the
PROCESS macro for the moderation analyses to calculate the conditional effects of emotional
blunting on Affect Naming and Emotional Stroop tasks. Bootstrap samples (n=10,000) and 95%
confidence intervals for the conditional effect were used to assess the stability and reliability of
moderation models.
3.3 Outlier, Normality, and Assumption Analysis
Data were assessed for skew and outliers and were examined to test the assumptions for analyses
utilizing general linear modelling. Box plots, stem-and-leaf plots, normal quantile-quantile (q-q
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plots), the Shapiro-Wilk Test statistic, and histograms with superimposed plotted normal curves
were used to assess for extreme outliers and to assess for the normality assumption of dependent
variables before inferential analysis. Skewness generally within -1 to 1 and kurtosis within -2 to
2 were used as acceptable values to help determine variables’ normality assumptions. High skew
(-2.26) was observed in scores on the Affect Naming task. After log transformation, skew was
reduced to an acceptable level (skew= .16) (Figures 1 and 2). Data were also assessed for
homogeneity of variance, heteroscedasticity, and multicollinearity. All assumptions for
regression analyses were met. All variables subsequently followed approximately normal
distributions without any significant outliers.
4. Results
4.1 Emotional Information Processing
To test the hypotheses that long-term SSRI-users differ in their cognition from control
subjects when processing emotional information (Aim 1), ANOVAs were conducted to
determine mean group differences in the Affect Naming and the Emotional Stroop tasks.
Contrary to the hypothesis that SSRI-users would have poorer accuracy in recognizing emotions
than controls (H1A), no differences were observed in mean Affect Naming accuracy scores,
F(1,121)=2.01, p=.159 (Table 2). While it was also hypothesized that SSRI-users would show
less variability compared to control subjects in reaction times based on the Emotional Stroop task
word valence (H1B), a general linear model revealed no differences between SSRI-users and
controls in the mean response times for neutral F(1,121)=0.01, p=.919), positive F(1,121)=0.00,
p=.989), and negative F(1,121)=0.03, p=.868) words (Table 2). Moreover, a supplemental
analysis determined that SSRI-users demonstrated no within-subject differences in their reaction
times to neutral, positive, or negative valence words, F(2,120)=0.98, p=.377.
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4.2 Emotional Blunting
To determine if SSRI-users with emotional blunting differed in cognitive processing of
emotional information compared to SSRI-users without emotional blunting (Aim 2), two data
analytic approaches were used. To test the hypothesis that long-term SSRI-users who reported
emotional blunting would have poorer accuracy in recognizing emotions than long-term SSRIusers who subjectively deny emotional blunting (2A), emotional blunting was first examined as a
continuous variable. Hypothesis 2A was not supported; OQUeSA scores were not significantly
correlated with scores on the Affect Naming task, r(61)=.10, p=.464. The second approach
transformed OQUeSA scores into an ordinal variable, as cut-off scores for the OQUeSA have
not been established, and a slight deviation from normality (skew=0.98) was observed (Figure 3).
As such, level of endorsed emotional blunting was re-categorized based on quartiles as
“none/low” (< 25th percentile, n=16), “moderate” (25th – 74th percentile, n=28) or “high” (> 75th
percentile, n=17). Results of these general linear models also did not support Hypothesis 2A, as
no differences were observed in mean Affect Naming scores between SSRI-users who reported
none/low, moderate, or high levels of emotional blunting F(2,58)=0.89, p=.417 (Table 3).
Contrary to Hypothesis 2B, predicting that SSRI-users who subjectively endorse emotional
blunting would show less variability in reaction times based on valence of words (positive,
neutral, and negative) than long-term SSRI-users who did not report emotional blunting, no
differences in mean reaction times on the Emotional Stroop task were observed, F(2,58)=0.16,
p=.852.
4.3 Antidepressant Effects as Perceived Cause of Emotional Blunting
To determine if SSRI-users who attribute their emotional blunting to their antidepressant
process information differently than SSRI-users who do not attribute their blunting to their
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antidepressant (Aim 3), two approaches were used. Similar to my approach in addressing Aim 2,
‘antidepressant as cause’ was first examined as a continuous variable based on the total subscale
score from the OQUeSA, followed by between-group examinations of the perceived cause
subscale score as an ordinal variable. Contrary to Hypothesis 3A, scores on the ‘antidepressant as
cause’ subscale were not correlated with the Affect Naming task score, r(61)=.03, p=.819. In the
second approach, “antidepressant as cause” scores were re-categorized as “none/low” (< 25th
percentile, n=23), “moderate” (25th – 74th percentile, n=22) or “high” (> 75th percentile, n=16). In
parallel to the correlational analysis, results did not support Hypothesis 3A as no differences in
mean Affect Naming scores were observed, F(2.58)=0.31, p=.736 (Table 4). Likewise, general
linear models revealed no differences in reaction times based on the emotional valence of words
presented in the Emotional Stroop task, F(2,58)=0.93, p=.401.
4.4 Sexual Dysfunction and Emotional Blunting
To determine if SSRI-users who reported sexual dysfunction (i.e., low libido and/or
difficultly/inability to orgasm) as a side effect were more likely to exhibit emotional blunting
than SSRI-users without sexual dysfunction (Aim 4), ANOVAs were conducted to compare
OQUeSA scores. Among the 61 SSRI-users, 37.7% (n=23) of them indicated that they had
current sexual dysfunction. Results indicated partial support for Hypothesis 4A: that SSRI-users
with sexual dysfunction would have higher levels of emotional blunting than long-term SSRIusers who did not endorse any sexual dysfunction side effects. SSRI-users with sexual
dysfunction had higher mean scores on the OQUeSA, F(1,60)=4.03, p=.049, which was driven
specifically by their higher scores on the “Not Caring” subscale of the OQUeSA, F(1,60)=9.93,
p=.003 (Table 5). These differences represent a medium effect size for total OQUeSA score (eta
squared= 0.64) and a large effect size for the “Not Caring” subscale (eta square = .144).
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4.5 Sexual Dysfunction and Emotional Information Processing
Aim 5 was to determine whether long-term SSRI-users who endorse sexual dysfunction
process emotional information differently. Hypothesis 5A that SSRI-users with sexual
dysfunction (n=23) would have poorer accuracy in recognizing emotions than long-term SSRIusers who do not report sexual dysfunction side effects (n=38) was not supported, F(1,61)=0.80,
p=.783 (Table 6). Support was also not observed for Hypothesis 5B – that SSRI-users who
subjectively endorse sexual dysfunction would show less variability in reaction times based on
valence of words (positive, neutral, and negative) than long-term SSRI-users who do not report
sexual dysfunction. No significant differences were present in the mean response times for
neutral, positive, or negative words among participants with sexual dysfunction, F(1,22)=0.98,
p=.757, or among those with no reported sexual dysfunction, F(1,37)=2.64, p=.113.
5. Discussion
5.1 Study Purpose
The primary purpose of this dissertation was to conduct an original study to elucidate the
impact of SSRI-induced emotional blunting in long-term SSRI-users and to determine if
individuals with emotional blunting demonstrate cognitive differences when processing
emotional information. Furthermore, this study attempted to determine if cognitive differences in
blunted individuals could serve as an objective marker of emotional blunting, as it is well known
that blunting overlaps with depression and has an insidious onset, making it difficult to
accurately detect. Lastly, this study also sought to determine if individuals with sexual
dysfunction secondary to SSRI use are at a heightened risk for emotional blunting.
This is an important addition to the literature, as many studies have identified the
limitations in self-report regarding emotional blunting, but no study has yet to establish a better
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standard in identifying emotional blunting in SSRI-users. Relatedly, the majority of past work on
blunting has not set clear exclusionary criteria for depression, leaving room for possible overlap
between depression symptoms and emotional blunting. This study excluded individuals with
active depression based on a clinically validated self-report measure to ensure that any cognitive
differences noted during emotional information processing could be directly attributed to SSRIinduced emotional blunting without the confounding variable of depression. Lastly, there is
currently no research on who may be most at risk for emotional blunting, such as SSRI-users
with sexual dysfunction. This study evaluated if SSRI-induced sexual dysfunction put users at
higher risk for blunting, which has not been previously examined.
5.2 On SSRI Use & Emotional Processing
Contrary to predictions, there were no differences in accuracy of identifying emotions
based on facial expressions or reaction times on an Affect Naming task and an Emotional Stroop
task between SSRI-users and controls. Because SSRI use has been associated with emotional
blunting, I hypothesized that SSRI-users would demonstrate poorer accuracy in recognizing
emotions via facial expressions. Similar work has found that women taking oral contraception
have poorer emotion recognition due to a blunting of reward responses and alterations in stress
response (Hamstra et al., 2014; Hamstra et al., 2016; Pahnke et al., 2019). While it was expected
that SSRI-users may exhibit similar difficulty in accurately identifying emotions when compared
to control subjects, accuracy differences were not seen in this study. No previous work exists on
the association between apathy (SSRI induced or otherwise) and reaction time on Emotional
Stroop tasks, but a large body of research supports the concept that individuals respond more
slowly on Emotional Stroop tasks when the words are personally relevant. For example, veterans
with PTSD demonstrate an attentional bias (slower response due to increased attention) for
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trauma-related words (Ashley et al., 2013). This pattern is also present in individuals with
clinically symptomatic Obsessive Compulsive Disorder (OCD), where individuals with
symptomatic OCD showed attentional bias (slower response) for negatively-valenced OCD
words when compared to individuals with remitted OCD (Rao et al., 2010). Additionally, a
systematic meta-analysis on Emotional Stroop effects and depression revealed an attentional bias
and slower response to negatively-valenced words in clinically depressed individuals when
compared to controls (Epp et al., 2012). In sum, the Emotional Stroop task appears to accurately
detect attentional bias towards stimuli due to mood or affect changes, with greatest bias and
slowest reaction times occurring when stimuli are personally relevant (Wingenfeld et al., 2006).
Given that SSRIs have the ability to potentially “numb” and blunt a person’s emotions, it was
anticipated that blunted individuals would exhibit smaller differences in reaction times based on
word valence due to blunting, akin to demonstrating the opposite of an attentional bias.
However, this study did not capture any differences in reaction times based on word valence
(positive, neutral, and negative), nor did it find any differences in overall mean reaction times
between SSRI-users and controls. Although the Emotional Stroop task was unable to identify
differences in emotional processing, the lack of differences in reaction time to word valence
suggests that SSRI-users in this study had adequately treated depression, in line with their BDI-II
scores. If SSRI-users were still experiencing depression, slower reaction times to negativelyvalenced words would have been captured, as seen in past research (Epp et al., 2012; Wingenfeld
et al., 2006).
5.3 On SSRI-induced Emotional Blunting & Emotional Processing
Also contrary to my predictions, there were no differences in accuracy of identifying
emotions based on facial expressions or reaction times on an Emotional Stroop task between
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SSRI-users who endorsed emotional blunting and SSRI-users who did not endorse emotional
blunting. Past research on apathy in Parkinson’s disease (PD) established that PD patients with
apathy exhibited deficits in recognizing facial expressions of fear, anger, and sadness, above and
beyond non-apathetic PD patients (Martinez-Corral et al., 2010). Similar work looking at apathy
in Lewy Body disease (LBD) found that higher levels of apathy were correlated with poorer
recognition of sad and angry facial expressions (Kojima et al., 2018). With SSRI-induced
blunting mirroring apathy, it was expected that individuals reporting SSRI-induced apathy would
demonstrate similar difficulty in facial affect recognition experienced by PD and LBD patients
(Ho et al., 2020). Contrary to previous work, it was not the case that SSRI-users with SSRIrelated emotional blunting had more difficulty recognizing facial expressions of emotions.
Likewise, this study did not find any differences in attentional bias and reaction time on the
Emotional Stroop task between SSRI-users who endorsed emotional blunting and SSRI-users
who did not endorse emotional blunting. It is plausible that cognitive measures just are not
sensitive enough to detect subtle differences in emotional processing or that SSRI-induced
blunting simply does not impact a person’s perception of emotion in their environment. Further
possibilities will be discussed in section 5.5.
5.4 On SSRI-induced Sexual Dysfunction & Emotional Processing
Past work has determined that approximately 80% of individuals with SSRI-induced
sexual dysfunction also report significant blunting of emotions (Opbroek et al., 2002). In parallel
with previous findings, the current study found that SSRI-users who are experiencing sexual
dysfunction were more likely to experience emotional blunting, as determined by scores on a
measure of SSRI-induced emotional blunting. Particularly, SSRI-users with sexual dysfunction
scored significantly higher on the “Not Caring” subscale of the OQuESA. This finding is in line
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with the past finding that SSRI-users with sexual dysfunction report less ability to care about
others’ feelings (Opbroek et al., 2002). Given this established correlation, this study also sought
to determine if SSRI-users with sexual dysfunction (low libido and/or difficulties with orgasm)
were more susceptible to differences in their ability to process emotional information. While it
was hypothesized that individuals with SSRI-induced sexual dysfunction would demonstrate
poorer accuracy in detecting facial expressions and less variability in reaction times based on
word valence compared to SSRI-users without sexual dysfunction, this study did not capture any
differences in reaction times based on word valence (positive, neutral, and negative), nor did it
find any differences in overall mean reaction times between SSRI-users with sexual dysfunction
and SSRI-users without sexual dysfunction. Overall, it appears that SSRI-users with SSRIinduced sexual dysfunction are more likely to experience emotional blunting, but emotional
blunting does not cause a negative impact on a person’s ability to accurately and efficiently
perceive emotional information.
One of the primary explanations for these results could be that SSRI-induced blunting
does not produce changes in basal ganglia-prefrontal cortex circuitry as is in PD, LBD, and
depression-related apathy. It is possible that SSRI-indued apathy does not disrupt the
aforementioned circuitry in the way disease-correlated apathy does. Instead, SSRI-induced
emotional blunting may be better explained by changes in neurotransmitter levels rather than
functional deficits in particular brain regions.
5.5 Nonsignificant Results
This study did not find any relationship between SSRI use and cognitive processing,
SSRI-induced emotional blunting and cognitive processing, or sexual dysfunction in SSRI-users
and cognitive processing. Given this pattern of nonsignificant findings, it is likely that SSRIs do
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not alter the way individuals perceive emotional stimuli. Past research has thoroughly
documented changes in the way one experiences their own emotions, but seldomly has
documented perception of emotional stimuli in one’s environment. For instance, a 2003 study
looked at changes in facial expression recognition after acute administration of an SSRI via
intravenous infusion in healthy adults. Results indicated that individuals who received citalopram
were able to accurately detect more faces with fear and happiness than their placebo control
counterparts, even after only 30 minutes of SSRI exposure (Harmer et al., 2003). While Hamer
and colleagues did not look at long-term SSRI use, their results suggest that exposure to an SSRI
can have an opposite effect from what was hypothesized here. Similar research on PD and facial
recognition also demonstrates inconsistent findings. Argaud and colleagues conducted a metaanalysis on PD patients (who frequently experience apathy) and facial expression recognition
and found a lack of consensus in the literature, with some studies citing deficits in emotion
recognition and others reporting intact emotion recognition (Argaud et al., 2018). Attentional
bias and emotional interference in PD have also been studied using Emotional Stroop Tasks.
While some studies note that non-depressed PD patients show differences in their reaction time
to Emotional Stroop tasks, most studies found that PD patients with depression are the only ones
to demonstrate changes, suggesting that depression is the main underlying factor influencing
emotional interference. One study specifically correlated depression and reaction time in PD
patients and found that only individuals with the highest level of depression exhibited differences
in reaction time to negative stimuli (Serra-Mestres & Ring, 1999). It is thus plausible that
cognitive differences as an effect of SSRI use are too small to quantify with the cognitive
measures used in this study. Specifically, the Affect Naming and Emotional Stroop tasks may not
be sensitive enough to measure cognitive differences in individuals with SSRI-induced
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emotional blunting, especially if SSRI-induced blunting does not disrupt circuitries often
implicated with apathy in neurological and psychiatric diseases such as the basal ganglia,
amygdala, and prefrontal cortex. It is also conceivable that cognitive differences in SSRI-users
with emotional blunting simply do not exist. There may be no connection between feeling one’s
own emotions being blunted and perceiving other emotional stimuli. Without that connection, it
is entirely possible that a person who cannot experience happiness, sadness, or anger strongly
could still accurately recognize those emotions in others and attend to emotional information
equally, regardless of the valence.
5.6 Generalizability of Findings
This study looked at cognitive differences and emotional blunting in long-term SSRIusers to ensure generalizability of findings. In reality, most patients stay on the drug for at least
12 months after recovery for maintenance and some remain on the medication for years due to
the long-term nature of depressive disorders, yet most empirical work on SSRI-induced cognitive
changes focuses on acute administration of SSRIs (Geddes et al., 2003). This study attempted to
fill a gap in the literature by focusing on long-term users to capture differences in the actual
target population and provide generalizability of findings. Relatedly, past work has looked at
acute administration of SSRIs in healthy control subjects. While this approach reduces
confounding variables, it does not capture findings that transfer well to real-world SSRI-users.
As such, this study investigated emotional changes associated with SSRI use in actual patients in
order to be more generalizable and reflective of real-world outcomes. More needs to be known
about long-term effects of SSRI-induced emotional blunting as research suggests that 75% of
individuals taking antidepressants are on the medication for at least a year (Hengartner et al.,
2020) and the side effect of blunting is often delayed (Reinblatt & Riddle, 2006).
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5.7 Limitations
The numerous strengths of this study (i.e., examining real-world SSRI-users, focusing on
long-term SSRI-users, excluding depressed individuals, and including diverse ethnicities) are
balanced by some limitations. First and foremost, the COVID-19 pandemic necessitated changes
to the original study design, including the exclusion of several neuropsychological measures (i.e.,
assessment of verbal memory for emotional content and verbal fluency). If this study was able to
be conducted in person, the ability to utilize additional neuropsychological measures would have
allowed for a more complete examination of cognitive changes and assessment of multiple
domains of cognition. Because SSRI-induced emotional blunting has significant overlap with
apathy in depression, including measures of executive functioning that are already proven to
change in depression would be a useful addition, as both depression and SSRI-induced apathy
disrupt fronto-limbic networks (Snyder, 2013).
While the Emotional Stroop Task specifically examined speed via reaction times,
including tests of other higher order cognitive processes such as set-shifting, impulse control,
and cognitive flexibility would provide a deeper examination of executive functioning, which is
the domain most susceptible to apathy and depression (Oliver et al., 2019; Shenal et al., 2003). A
2013 meta-analysis of 113 studies of broad executive functioning in depression revealed an
association between MDD and neuropsychological performance, such that more severe
depression was associated with greater levels of impairment in executive functioning (Snyder,
2013). To provide a more thorough investigation of executive functioning in SSRI-induced
blunting, including a pure measure of processing speed (e.g., Trails A), a measure of working
memory (e.g., digits backwards), and measures of cognitive flexibility and reasoning (e.g.,
Wisconsin Card Sorting Task and Trails B) would be beneficial. Along with a more thorough
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investigation of executive functioning, it would also have been beneficial to include cognitive
tasks that tap into other domains of functioning, such as language and memory. Previous
research in depression has established impairment in memory, as learning and initial encoding of
information is mediated by frontal lobe systems (Mohn & Rund, 2016). Multiple studies have
documented verbal memory deficits in individuals with MDD, particularly for emotionallyvalenced information, as individuals with depression exhibit an attentional bias for negative
information. This attentional bias is known to enhance memory for negative material and impair
memory for positive information (Burt et al., 1995; Dillon & Pizzagali, 2018). Incorporating
memory tasks for both emotionally-charged and non-emotional information would be valuable
additions to the literature, given that this study is the first to attempt to quantify objective
cognitive differences in SSRI-users with emotional blunting. Likewise, incorporating a task of
semantic fluency, which is a task of language well-known to be negatively impacted by apathy
due to its reliance on frontal subcortical system functioning, would have allowed this study to
demonstrate possible language deficits in SSRI-induced emotional blunting (Fossati et al., 2003;
Fishman et al., 2017).
Emotional blunting is only newly recognized as a side effect of SSRI use and has been
negligibly investigated. Most studies, to date, have attempted to confirm SSRI-induced
emotional blunting as a legitimate construct and document it anecdotally rather than looking at
ways to objectively identify its presence. The COVID-19 pandemic also forced this study to
discontinue all physiological data collection. I originally intended to collect heart rate, respiration
rate, and skin conductance on both long-term SSRI-users and control subjects while they were
exposed to emotionally charged video and audio stimuli. Looking at physiological responses
would be the most objective way of assessing emotional blunting, as it less susceptible to
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conscious awareness. While it was hoped that there was minimal conscious awareness of what
was being measured during the Emotional Stroop task and the Affect Naming task, it is possible
that individuals in the study were consciously aware of the emotional content being presented.
This study would have benefited from a larger sample size with matched demographics.
Originally, data from 227 participants were collected. After evaluation of depression based on
BDI-II scores, almost 50% of the originally collected sample was excluded due to elevated
depression (BDI-II scores greater than 13). According to the National Institute of Mental Health
(2019), the typical prevalence rate of depression in the United States in 2019 was 7.8%, a
drastically lower amount than the approximately 50% seen in this study. The larger number of
individuals with clinically significant depression seen in this study may have been due to the
COVID-19 pandemic. Data were collected in July of 2020 when the country was in a state of
pandemic-related distress, with no approved vaccinations and uncertainty for the future. After
exclusion, this study’s SSRI group contained significantly more females, older participants, and
more gay/lesbian participants. The SSRI group also only had one Asian participant where the
control group had 11 Asian participants. In future studies, matching participants on demographic
characteristics would be advantageous to ensure group differences on cognitive tasks were not
impacted by demographic variability.
While this study had a notably higher sample of SSRI-users than most previous work,
only 17 SSRI-users endorsed high levels of emotional blunting on the OQUeSA. This sample
size is comparable with past work, but a larger sample with at least 50 participants reporting high
emotional blunting would have been beneficial. To better address the overlap in depression and
SSRI-induced emotional blunting and sample size simultaneously, future work should include a
depressed group without SSRI-induced emotional blunting and a depressed group with SSRI-
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induced emotional blunting. By including these additional independent variables, future research
would be able to capture distinct differences in cognition in depression independently, SSRIinduced emotional blunting independently, and deduce which domains of cognition are
susceptible to impact by both depression and SSRI-induced blunting. In the current initial work,
excluding individuals with active depressive symptomology still on SSRIs was imperative to
acquire a “pure” group SSRI-induced blunted individuals without depression. While I would
expect similar disruptions given that these syndromes both impact similar fronto-subcortical
neural circuitry, it would be meaningful to collect and analyze data on these sets of individuals to
determine the level of impact and gather information on moderation effects.
Another limitation of this study was the lack of exclusion of individuals taking oral
contraception. This is an issue because oral contraception is known to potentially induce a degree
of emotional blunting. For instance, one study found that women taking oral contraception
showed blunted cortisol response when being shown emotionally arousing images (Nielsen et al.,
2013). Another study found that hormonal contraception blunted reward response and
dysregulated the stress response in women resulting in impaired recognition of facial emotion
recognition, particularly for negative emotions when compared to naturally cycling women
(Hamstra et al., 2014; Hamstra et al., 2016; Pahnke et al., 2019). By removing subjects on oral
contraception, a confounding variable would be eliminated; therefore, one would have more
confidence that the results and conclusions made about SSRI-induced emotional blunting would
be specific to SSRI use alone.
Assessing depression as a condition of state and trait would also be advantageous. The
current study utilized the golden standard self-report measure for assessing clinically significant
depression (i.e., BDI-II). While clinical depression is seen as a persisting (longer than two
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weeks) state of sadness and anhedonia, future work could add another self-report measure of
mood, particularly one that can capture state affect to ensure subject’s potential elevation in
depression is a true clinical disorder rather than a transient negative affect. The Positive and
Negative Affect Schedule (PANAS; Watson et al., 1988) is a well-known measure that is used in
emotion research and is sensitive to brief fluctuations in mood (Magyar-Moe, 2009). Adding the
PANAS in future work would provide greater information on how fleeting emotional state
potentially affects executive functioning and overall cognitive performance in individuals on
SSRIs.
In designing a study that is conducted in a completely remote fashion, it is difficult to
control for engagement and distractors in the environment. Thus, another limitation of the study
is that it was not possible to control for participants not engaging in other tasks during the
cognitive tasks (i.e., using their phones, having loud noises in the background). While I included
attention checks, having participants complete the cognitive tests in person would have ensured
proper study engagement and standardized the environment across all subjects.
This study did not examine the effects of SSRI dosage on SSRI-induced blunting, which
may be a limitation. Considering dosage in future studies will be beneficial to prescribers, as
emotional blunting is a dose-dependent side effect. While dosage of medication is based on
individual factors, such as weight and diagnosis, attempting to identify general dosages that
make someone most vulnerable to emotional blunting would be critically important to educating
prescribers about the frequency and prevalence of emotional blunting. Knowing what dosages
are most likely to induce blunting would allow prescribers to heighten their vigilance and
potentially probe for the presence of blunting. The onus of detecting emotional blunting truly
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falls on the prescriber, as the onset and development is insidious and often is not identified and
articulated by SSRI-users (Opbroek et al., 2002).

5.8 Future Directions
While cognitive processing of emotions was not found to be an effective way to measure
emotional blunting, the need to identify an objective measure of emotional blunting remains
essential to help SSRI-users avoid social disruptions or changes to their daily social functioning.
Past work has demonstrated that physiological functioning changes as a function of emotion
(Diemer et al., 2016; Lohani et al., 2018) and under the influence of certain drugs ranging from
nicotine and marijuana to anti-epileptics (Cooper & Haney, 2009; Lotufo et al., 2012; Valjent et
al., 2002). Relationships between viewing emotional pictures or words and changes in
cardiovascular and electrodermal responses are well documented (Bernat et al., 2001; Lang et al.,
1993). Physiological responses such as heart rate, respiration rate, and/or skin conductance are
often relied upon because evoked autonomic or somatic responses occur based on perceptions. In
other words, based on one’s perception of the situation, the body differentially determines how to
appropriately respond physiologically and psychologically (Fujimura et al., 2013). Given that the
autonomic system is clearly influential in emotional responding, the study of physiological
reactions in the context of SSRI use and emotional blunting may be a viable objective target for
future research.
Better understanding of the underlying mechanisms of SSRI-induced emotional blunting
should be also elucidated. Research looking at functional changes in the brain in long-term
SSRI-users with and without emotional blunting is needed to determine if SSRI-induced
emotional blunting affects the brain differently from apathy seen in other neurological and
psychiatric populations. Past fMRI studies have focused on changes in emotional processing
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with acute administration SSRIs (Takahashi et al., 2005; Tranter et al., 2009). Changes in
activation of the amygdaloid-hippocampal regions, orbitofrontal cortex, basal ganglia, and insula
were observed when individuals given acute SSRI administration viewed emotionally charged
images. Utilizing similar study designs, future work should seek to uncover the functional
changes (via fMRI) associated with SSRI-induced emotional blunting to make comparisons to
apathy in other contexts. Further understanding of the underlying neural mechanisms of SSRIinduced emotional blunting would inform future work attempting to objectively identify
emotional blunting. To isolate SSRI-induced apathy from depression, future studies should
continue to exclude individuals with sustained depression, instead of studying individuals on
SSRIs for maintenance with remitted symptomatology.
All in all, this is the first study attempting to assess cognitive differences in SSRI-induced
emotional blunting and emotional blunting in long-term SSRI-users with remitted depression.
While the results suggested that there are no cognitive differences between SSRI-users with and
without emotional blunting and between SSRI-users with and without sexual dysfunction, future
research considering the functional neural mechanisms behind SSRI-induced emotional blunting
may help elucidate better ways to objectively measure its presence. This study furthers the
scientific literature by stressing the need for generalizability of findings in long-term SSRI-users
and moving beyond self-report for SSRI-induced emotional blunting. To propel the literature on
SSRI-induced emotional blunting, future work needs to focus on empirical documentation,
neuroanatomical functioning, and subsequent social, physical, and cognitive changes produced
by emotional blunting. Additionally, although there were no differences among cognitive
measures in this study, this does not mean that future attempts to document differences using
other cognitive measures or focusing on physiological changes in SSRI-users with emotional
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blunting will not be fruitful. It is possible that the measures chosen in this study were not
sensitive enough to capture subtle cognitive changes. Specifically, the Emotional Stroop Task
captures lags in reaction time to emotional stimuli which are driven by attentional bias. In past
work, the utilization of the Emotional Stroop Task is carefully crafted to make target words
personally relevant to the sample group. For example, studies looking at PTSD from active
combat often use words like bomb, death, and explosion, as these words contain the emotional
salience needed to draw the responder’s attention which is known to be the most important factor
when creating an Emotional Stroop Task (Wingenfeld et al., 2006). Similarly, studies focused on
a sample of individuals with social phobia would alternatively choose words such as stutter,
embarrassment, or speech. While the premise of attentional bias remains the same, the words
used to cause the bias is not standardized (Wingenfeld et al., 2006). In this study, negative and
positive words were chosen from four previously validated Emotional Stroop Tasks. The words
chosen tapped into multiple facets of positivity and negativity rather than a specific focus on
personal salience. Because personal relevance impacts attentional biases seen in responders, this
study may not have captured significant response time differences intra-individually due to the
lack of personalization of stimuli. In the future, researchers may consider assessing personal
relevance to varying emotional states (e.g., finding what scares someone and using that as
negative condition). With this said, tailoring of emotional stimuli may not be applicable in this
sample, as SSRI-induced blunting is not inherently emotionally-charged. Indeed, it is the
absence of emotional responsiveness when one would be typical or expected. Given its flat
characteristic, using more specific and relevant words may not be possible, as it would be in
research on MDD, specific phobias, and PTSD. In fact, research has demonstrated that

52

individuals with pure apathy (without depression) have decreased salience networks in the brain
(Yuen et al., 2014).
Along with salience/relevance issues, the Emotional Stroop Task has been shown to lack
test-retest reliability in both healthy control subjects and multiple clinical samples (Dresler et al.,
2012; Eide et al., 2002). To address reliability in the future, an Emotional Stroop interference
score could be calculated (e.g., reaction time negative – reaction time neutral; reaction time
positive – reaction time neutral; and reaction time of all positive and negative – reaction time
neutral). By creating interference scores, one could test reliability using the split-half method.
While only longitudinal studies with multiple time points can truly address test-retest reliability
of the Stroop interference effect, past studies lacking multiple time points have attempted to
compare internal split-half reliability to longitudinal findings to ensure reliability is comparable
(Dresler et al., 2008; Eide et al., 2002).
To mitigate the limitations of the Emotional Stroop Task, future work may wish to focus
on executive functioning more broadly rather than solely in the context of emotional stimuli.
Depression is well known to impact multiple aspects of executive functioning such as processing
speed, learning and encoding, and organization, even when information lacks emotional charge
(Fossati et al., 2003). With these associations well-documented, perhaps future work can expand
upon the current study and additionally explore executive functioning with emotionally
uncharged information. For example, adding in a list-learning task of words (e.g., California
Verbal Learning Test- Version 3) would provide information on memory functioning, but also on
subjects’ encoding and organization strategies. Along the same lines, future research may wish to
examine processing speed outside of emotional words, such as using the Trails A & B tests, to
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determine if psychomotor processing speed in SSRI-induced apathy exhibits similar patterns to
depression.
In fact, my hope is that this study is one of many future empirical studies to expand upon
previous anecdotal reports of SSRI-induced apathy and that this study just begins the journey of
using neuropsychological measures to quantify changes in individuals with SSRI-induced
emotional blunting. Along with the need to further study SSRI-induced emotional blunting
empirically to find quantifiable ways to measure its presence, there is also a need to continue
researching the correlation between SSRI-induced sexual dysfunction and SSRI-induced
emotional blunting as this study found that individuals on SSRIs with sexual dysfunction are at
an increased risk of experiencing blunting. Future work on SSRI-induced blunting might focus
on this vulnerable population of individuals taking the drug. Ultimately, this study met its aim of
empirically studying SSRI use and its side effects, and it demonstrated the importance of
considering ways to quantify emotional blunting beyond self-report.
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6.1 TABLES
Table 1
Sociodemographic characteristics in a sample of adults with and without current SSRI use
(N=122)
SSRI Use
Controls
(N=61)
(N=61)
Characteristic
n (%)
n (%)
Statistic(df)
p
2
Sex
.001
 (2)=14.02
Male
19 (31.1%)
38 (62.3%)
Female
38 (62.3%)
23 (37.7%)
Other
4 (6.6%)
0 (0.0%)
Age
F(1,120=6.67
.011
Mean (SD)
38.26 (14.50) 32.10 (11.70)
Race
.038
2(4)=10.18
White
53 (86.9%)
41 (67.2%)
Black
4 (6.6%)
5 (8.2%)
Asian
1 (1.6%)
11 (18.0%)
American Indian/Native
1 (0.9%)
1 (1.6%)
Alaskan
Other
2 (3.3%)
3 (4.9%)
Sexual Orientation
.019
2(3)=10.01
Heterosexual
43 (70.5%)
56 (91.8%)
Gay
7 (11.5%)
1 (1.6%)
Bisexual
8 (13.1%)
2 (3.3%)
Other
3 (4.9%)
2 (3.3%)
Current Romantic Relationship
1.00
2(1)=0.00
Yes
39 (63.9%)
39 (63.9%)
No
22 (36.1%)
22 (36.1%)
Annual Household Income
.685
2(6)=3.94
$30,000 or less
15 (24.6%)
11 (18.0%)
$30,000 – $50,000
12 (19.7%)
7 (11.5%)
$50,000 – $70,000
10 (16.4%)
13 (21.3%)
$70,000 – $90,000
7 (11.5%)
10 (16.4%)
$90,000 – $125,000
7 (11.5%)
11 (18.0%)
$125,000 – $175,000
7 (11.5%)
7 (11.5%)
$175,000 or more
3 (4.9%)
2 (3.3%)
Depression and Anxiety
BDI-II score, Mean (SD)
6.34 (3.644)
7.29 (3.98)
F(1,121)=1.90
.171
BAI score, Mean (SD)
6.82 (6.84)
4.70 (5.21)
F(1,121)3.682
.057
BDI-II (Beck Depression Inventory-II); BAI (Beck Anxiety Inventory)
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Table 2
Comparisons in Stroop emotional word task and affect naming in adults with and without
current SSRI use (N=122)
SSRI-users
Controls
(N=61)
(N=61)
Characteristic
M (SD)
M (SD)
Statistic(df)
p
Stroop response time (msec)
Neutral
863.55
866.54
F(1,121)=0.01
.919
(170.04)
(154.15)
Positive
873.31
872.88
F(1,121)=0.00
.989
(171.58)
(165.49)
Negative
860.50
865.20
F(1,121)=0.03
.868
(166.87)
(143.29)
Affect naming accuracy
20.13 (3.60)
20.95 (2.72)
F(1,121)=2.01
.159

Table 3
Comparisons in Stroop emotional word task and affect naming by level of self-reported level of emotional
blunting as measured by the OQUeSA among SSRI-users (N=61)
Level of emotional blunting
None/Low
Moderate
High
(N=16)
(N=28)
(N=17)
Characteristic
M (SD)
M (SD)
M (SD)
Statistic(df)
p
Stroop response time
(msec)
Neutral
895.68
838.73
920.82
F(2.58)=1.94
.153
(160.54)
(146.36) (163.87)
Positive
877.52
853.56
926.18
F(2.58)=0.28
.758
(174.96)
(158.52) (178.84)
Negative
878.75
849.13
899.85
F(2.58)=0.36
.700
(152.28)
(145.24) (132.12)
Affect naming accuracy
21.33 (1.15)
19.94 (3.64)
19.54 (4.81)
F(2.58)=0.89
.417
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Table 4
Comparisons in Stroop emotional word task and affect naming by level of perceived “antidepressant as cause
of emotional blunting” as measured by the OQUeSA among SSRI-users (N=61)
Level of emotional blunting
None/Low
Moderate
High
(N=23)
(N=22)
(N=16)
Characteristic
M (SD)
M (SD)
M (SD)
Statistic(df)
p
Stroop response time
(msec)
Neutral
893.60
822.97
876.13
F(2.58)=1.03
.363
(177.44)
(169.79) (158.57)
Positive
896.64
836.06
890.99
F(2.58)=0.81
.449
(165.94)
(174.97) (176.94)
Negative
885.06
825.46
873.37
F(2.58)=0.78
.465
(158.95)
(181.80) (158.59)
Affect naming accuracy
21.26 (2.09)
20.91 (2.43)
20.56 (3.81)
F(2.58)=0.31
.736

Table 5
Comparisons in levels of self-reported blunting among SSRI-users by endorsement of sexual
dysfunction (N=61)
Sexual Dysfunction
Yes
No
(N=23)
(N=38)
Characteristic
M (SD)
M (SD)
Statistic(df)
p
Oxford Depression Questionnaire
Total score
44.17
35.45
F(1,60)=4.03
.049
(19.56)
(14.27)
General reduction in emotions
11.78 (5.54)
9.89 (4.42)
F(1,60)=2.15
.148
Reduction in positive emotions
12.13 (6.38)
9.71 (4.95)
F(1,60)=2.75
.103
Emotional detachment from
9.04 (5.06)
8.10 (4.14)
F(1,60)=0.621
.434
others
Not caring
11.22 (5.17)
7.74 (3.46)
F(1,60)=9.93
.003
Antidepressant as cause
10.74 (5.66)
9.34 (4.51)
F(1,60)=1.13
.292
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Table 6
Comparisons in Stroop emotional word task and affect recognition among SSRI-users by
endorsement of sexual dysfunction as measure of emotional blunting (N=61)
Sexual Dysfunction
Yes
No
(N=23)
(N=38)
Characteristic
M (SD)
M (SD)
Statistic(df)
Stroop response time (msec)
Neutral
884.66
850.76
F(1,61)=0.56
(184.83)
(161.64)
Positive
886.84
865.12
F(1,61)=0.23
(191.61)
(160.39)
Negative
882.97
846.90
F(1,61)=0.67
(182.54)
(157.60)
Affect naming accuracy
20.83 (3.47)
21.03 (2.18)
F(1,61)=0.80

Table 7
Effect of emotional blunting as a moderator of SSRI status on Stroop emotional word task
and affect recognition
95% CI
Model
Estimate Std. Err.
t
P
Lower Upper
Stroop neutral words
SSRI status
-3.93
29.57
-.13
.89
-62.49 54.63
OQUESA score
1.24
1.00 1.25
.21
-0.73
3.22
SSRI status x OQUESA
.17
2.00
.08
.93
-3.79
4.12
score
Stroop positive words
SSRI status
-0.73
30.62
-.02
.98
-61.38 59.92
OQUESA score
1.54
1.03
1.49
.14
-0.50
3.59
SSRI status x OQUESA
-.06
2.07
-.03
.97
-4.16
4.03
score
Stroop negative words
SSRI status
-5.53
28.26
-.20
.84
-61.52 50.45
OQUESA score
1.11
.95 1.16
.25
-0.78
3.00
SSRI status x OQUESA
1.27
1.90
.72
.47
-2.41
5.15
score
Affect recognition
SSRI status
-.83
.58 1.43
.15
-0.32
1.97
OQUESA score
-.02
.02 -1.27
.21
-0.06
0.01
SSRI status x OQUESA
-.01
.04 -0.02
.99
-0.08
0.07
score
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p
.455
.636
.418
.783

Table 8
Comparisons in levels of self-reported blunting in adults with and without current SSRI use
(N=122)
SSRI-users
Controls
(N=61)
(N=61)
Characteristic
M (SD)
M (SD)
Statistic(df)
p
Oxford Depression Questionnaire
Total score
38.74
38.33 F(1,121)=0.22
.883
(16.85)
(13.71)
General reduction in emotions
10.61 (4.92)
10.05 (4.14) F(1,121)=0.46
.500
Reduction in positive emotions
10.62 (5.61)
9.98 (4.27) F(1,121)=0.50
.480
Emotional detachment from
8.46 (4.49)
9.24 (4.07) F(1,121)=1.03
.313
others
Not caring
9.05 (4.48)
9.04 (4.10) F(1,121)=0.00
1.00
Antidepressant as cause
9.87 (4.97)
NA*
NA*
* Control participants were not administered the antidepressant as cause component of the
Oxford Depression Questionnaire.

Table 9
Descriptive Statistics of Primary Measures (N= 122)
Range

Minimum

Maximum

Mean

SD

OQUeSA Blunting Scores

69

20

89

38.5328

15.2977

BDI Total Scores

12

1

13

6.8197

3.82902

BAI Total Scores

28

0

28

5.7623

6.15106

Affect Naming Scores

18

6

24

20.541

3.2042

Stroop: Neutral RT

637.77

549.87

1187.65

865.0311

161.68597

Stroop: Positive RT

698.73

520.21

1218.94

873.0969

167.88233

Stroop: Negative RT

652.97

544.61

1197.58

862.8307

154.99356

59

6.2 FIGURES

60

61

6.3 REFERENCES
Alarcón R. D., & Preskorn, S. (2004). Antidepressants: past, present, and future. (pp. 421-446) Springer.
Amariglio, R. E., Donohue, M. C., Marshall, G. A., Rentz, D. M., Salmon, D. P., Ferris, S. H.,
Karantzoulis, S., Aisen, P. S., & Sperling, R. A. (2015). Tracking Early Decline in Cognitive
Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 72(4),
446. https://doi.org/10.1001/jamaneurol.2014.3375
Anderson, S., Krogstad, J. M., & Finset, A. (1999). Apathy and depressed mood in acquired brain
damage: relationship to lesion localization and psychophysiological reactivity. Psychological
Medicine, 29(2), 447–456. https://doi.org/10.1017/s0033291798008046
Apostolova, L. G., & Cummings, J. L. (2007). Neuropsychiatric Manifestations in Mild Cognitive
Impairment: A Systematic Review of the Literature. Dementia and Geriatric Cognitive
Disorders, 25(2), 115–126. https://doi.org/10.1159/000112509
Argaud, S., Vérin, M., Sauleau, P., & Grandjean, D. (2018). Facial emotion recognition in Parkinson’s
disease: A review and new hypotheses. Movement Disorders, 33(4), 554–567.
https://doi.org/10.1002/mds.27305
Ashley, V., Honzel, N., Larsen, J., Justus, T., & Swick, D. (2013). Attentional bias for trauma-related
words: exaggerated emotional Stroop effect in Afghanistan and Iraq war veterans with PTSD.
BMC Psychiatry, 13(1). https://doi.org/10.1186/1471-244x-13-86
Balon, R. (2006). SSRI-Associated Sexual Dysfunction. American Journal of Psychiatry, 163(9), 1504–
1509. https://doi.org/10.1176/ajp.2006.163.9.1504
Barnhart, W. J., Makela, E. H., & Latocha, M. J. (2004). SSRI-Induced Apathy Syndrome: A Clinical
Review. Journal of Psychiatric Practice, 10(3), 196–199. https://doi.org/10.1097/00131746200405000-00010

62

Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety:
Psychometric properties. Journal of Consulting and Clinical Psychology, 56(6), 893–897.
https://doi.org/10.1037/0022-006x.56.6.893
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory-II. San Antonio, 78(2), 490498.
Becker, E. S., Rinck, M., Margraf, J., & Roth, W. T. (2001). The emotional Stroop effect in anxiety
disorders. Journal of Anxiety Disorders, 15(3), 147–159. https://doi.org/10.1016/s08876185(01)00055-x
Bennabi, D., Vandel, P., Papaxanthis, C., Pozzo, T., & Haffen, E. (2013). Psychomotor Retardation in
Depression: A Systematic Review of Diagnostic, Pathophysiologic, and Therapeutic Implications.
BioMed Research International, 2013, 1–18. https://doi.org/10.1155/2013/158746
Berkman, L., & Glass, T. (2000). Social integration, social networks, social support, and health. Social
Epidemiology, 1(6), 137–173.
Bernat, E., Bunce, S., & Shevrin, H. (2001). Event-related brain potentials differentiate positive and
negative mood adjectives during both supraliminal and subliminal visual processing.
International Journal of Psychophysiology, 42(1), 11–34. https://doi.org/10.1016/s01678760(01)00133-7
Biver, F., Wikler, D., Lotstra, F., Damhaut, P., Goldman, S., & Mendlewicz, J. (1997). Serotonin 5-HT2
receptor imaging in major depression: focal changes in orbito-insular cortex. British Journal of
Psychiatry, 171(5), 444–448. https://doi.org/10.1192/bjp.171.5.444
Bolling, M. Y., & Kohlenberg, R. J. (2004). Reasons for Quitting Serotonin Reuptake Inhibitor Therapy:
Paradoxical Psychological Side Effects and Patient Satisfaction. Psychotherapy and
Psychosomatics, 73(6), 380–385. https://doi.org/10.1159/000080392
Bradley, M. M., Cuthbert, B. N., & Lang, P. J. (1996). Picture media and emotion: Effects of a sustained
affective context. Psychophysiology, 33(6), 662–670. https://doi.org/10.1111/j.14698986.1996.tb02362.x

63

Brown, T. A., Campbell, L. A., Lehman, C. L., Grisham, J. R., & Mancill, R. B. (2001). Current and
lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample.
Journal of Abnormal Psychology, 110(4), 585–599. https://doi.org/10.1037/0021-843x.110.4.585
Burghardt, N. S., & Bauer, E. P. (2013). Acute and chronic effects of selective serotonin reuptake
inhibitor treatment on fear conditioning: Implications for underlying fear circuits. Neuroscience,
247, 253–272. https://doi.org/10.1016/j.neuroscience.2013.05.050
Burt, D. B., Zembar, M. J., & Niederehe, G. (1995). Depression and memory impairment: A metaanalysis of the association, its pattern, and specificity. Psychological Bulletin, 117(2), 285–305.
https://doi.org/10.1037/0033-2909.117.2.285
Cameron, J. J., Stinson, D. A., & Wood, J. V. (2013). The Bold and the Bashful. Social Psychological
and Personality Science, 4(6), 685–691. https://doi.org/10.1177/1948550613476309
Cascade, E., Kalali, A. H., & Kennedy, S. H. (2009). Real-World Data on SSRI Antidepressant Side
Effects. Psychiatry, 6(2), 16–18.
Cassano, G. B., Puca, F., Scapicchio, P. L., & Trabucchi, M. (2002). Paroxetine and Fluoxetine Effects
On Mood and Cognitive Functions in Depressed Nondemented Elderly Patients. The Journal of
Clinical Psychiatry, 63(5), 396–402. https://doi.org/10.4088/jcp.v63n0504
Chamberlain, S. R., Müller, U., Robbins, T. W., & Sahakian, B. J. (2006). Neuropharmacological
modulation of cognition. Current Opinion in Neurology, 19(6), 607–612.
https://doi.org/10.1097/01.wco.0000247613.28859.77
Channon, S., & Green, P. S. S. (1999). Executive function in depression: the role of performance
strategies in aiding depressed and non-depressed participants. Journal of Neurology,
Neurosurgery & Psychiatry, 66(2), 162–171. https://doi.org/10.1136/jnnp.66.2.162
Constant, E. L., Adam, S., Gillain, B., Seron, X., Bruyer, R., & Seghers, A. (2005). Effects of sertraline
on depressive symptoms and attentional and executive functions in major depression. Depression
and Anxiety, 21(2), 78–89. https://doi.org/10.1002/da.20060

64

Cooper, Z. D., & Haney, M. (2009). Comparison of subjective, pharmacokinetic, and physiological
effects of marijuana smoked as joints and blunts. Drug and Alcohol Dependence, 103(3), 107–
113. https://doi.org/10.1016/j.drugalcdep.2009.01.023
den Brok, M. G., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de Bie, R. M., & Richard,
E. (2015). Apathy in Parkinson’s disease: A systematic review and meta-analysis. Movement
Disorders, 30(6), 759–769. https://doi.org/10.1002/mds.26208
Diemer, J., Lohkamp, N., Mühlberger, A., & Zwanzger, P. (2016). Fear and physiological arousal during
a virtual height challenge—effects in patients with acrophobia and healthy controls. Journal of
Anxiety Disorders, 37(37), 30–39. https://doi.org/10.1016/j.janxdis.2015.10.007
Dillon, D. G., & Pizzagalli, D. A. (2018). Mechanisms of Memory Disruption in Depression. Trends in
Neurosciences, 41(3), 137–149. https://doi.org/10.1016/j.tins.2017.12.006
Dresler, T., Ehlis, A.-C. ., Hindi Attar, C., Ernst, L. H., Tupak, S. V., Hahn, T., Warrings, B., Markulin,
F., Spitzer, C., Löwe, B., Deckert, J., & Fallgatter, A. J. (2012). Reliability of the emotional
Stroop task: An investigation of patients with panic disorder. Journal of Psychiatric Research,
46(9), 1243–1248. https://doi.org/10.1016/j.jpsychires.2012.06.006
Dresler, T., Mériau, K., Heekeren, H. R., & Meer, E. (2008). Emotional Stroop task: effect of word
arousal and subject anxiety on emotional interference. Psychological Research Psychologische
Forschung, 73(3), 364–371. https://doi.org/10.1007/s00426-008-0154-6
Eide, P., Kemp, A., Silberstein, R. B., Nathan, P. J., & Stough, C. (2002). Test-Retest Reliability of the
Emotional Stroop Task: Examining the Paradox of Measurement Change. The Journal of
Psychology, 136(5), 514–520. https://doi.org/10.1080/00223980209605547
Epp, A. M., Dobson, K. S., Dozois, D. J. A., & Frewen, P. A. (2012). A systematic meta-analysis of the
Stroop task in depression. Clinical Psychology Review, 32(4), 316–328.
https://doi.org/10.1016/j.cpr.2012.02.005

65

Evers, E. A., van der Veen, F. M., Jolles, J., Deutz, N. E., & Schmitt, J. A. J. (2006). Acute tryptophan
depletion improves performance and modulates the BOLD response during a Stroop task in
healthy females. NeuroImage, 32(1), 248–255. https://doi.org/10.1016/j.neuroimage.2006.03.026
Fales, C. L., Barch, D. M., Rundle, M. M., Mintun, M. A., Mathews, J., Snyder, A. Z., & Sheline, Y. I.
(2009). Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during
emotional interference processing in major depression. Journal of Affective Disorders, 112(1-3),
206–211. https://doi.org/10.1016/j.jad.2008.04.027
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power
analysis program for the social, behavioral, and biomedical sciences. Behavior Research
Methods, 39(2), 175–191. https://doi.org/10.3758/bf03193146
Ferguson, J. M. (2001). SSRI Antidepressant Medications: Adverse Effects and Tolerability. Primary
Care Companion to the Journal of Clinical Psychiatry, 3(1), 22–27.
https://doi.org/10.4088/pcc.v03n0105
Fisher, H., Aron, A., & Brown, L. L. (2005). Romantic love: An fMRI study of a neural mechanism for
mate choice. The Journal of Comparative Neurology, 493(1), 58–62.
https://doi.org/10.1002/cne.20772
Fishman, K. N., Ashbaugh, A. R., Lanctôt, K. L., Cayley, M. L., Herrmann, N., Murray, B. J., Sicard, M.,
Lien, K., Sahlas, D. J., & Swartz, R. H. (2017). Apathy, not depressive symptoms, as a predictor
of semantic and phonemic fluency task performance in stroke and transient ischemic attack.
Journal of Clinical and Experimental Neuropsychology, 40(5), 449–461.
https://doi.org/10.1080/13803395.2017.1371282
Fortney, J. C., Pyne, J. M., Edlund, M. J., Stecker, T., Mittal, D., Robinson, D. E., & Henderson, K. L.
(2010). Reasons for Antidepressant Nonadherence Among Veterans Treated in Primary Care
Clinics. The Journal of Clinical Psychiatry, 72(06), 827–834.
https://doi.org/10.4088/jcp.09m05528blu

66

Fossati, P., Bastard Guillaume, L., Ergis, A.-M., & Allilaire, J.-F. (2003). Qualitative analysis of verbal
fluency in depression. Psychiatry Research, 117(1), 17–24. https://doi.org/10.1016/S01651781(02)00300-1
Fujimura, T., Katahira, K., & Okanoya, K. (2013). Contextual Modulation of Physiological and
Psychological Responses Triggered by Emotional Stimuli. Frontiers in Psychology, 4(4).
https://doi.org/10.3389/fpsyg.2013.00212
Garland, E. J., & Baerg, E. A. (2001). Amotivational Syndrome Associated with Selective Serotonin
Reuptake Inhibitors in Children and Adolescents. Journal of Child and Adolescent
Psychopharmacology, 11(2), 181–186. https://doi.org/10.1089/104454601750284090
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M.
(2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a
systematic review. The Lancet, 361(9358), 653–661. https://doi.org/10.1016/s01406736(03)12599-8
Gitlin, M. (1994). Psychotropic medications and their effects on sexual function: diagnosis, biology, and
treatment approaches. The Journal of Clinical Psychiatry, 55(9), 406–413.
Godlewska, B. R., Browning, M., Norbury, R., Cowen, P. J., & Harmer, C. J. (2016). Early changes in
emotional processing as a marker of clinical response to SSRI treatment in depression.
Translational Psychiatry, 6(11), e957–e957. https://doi.org/10.1038/tp.2016.130
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017). Emotional blunting with antidepressant
treatments: A survey among depressed patients. Journal of Affective Disorders, 221(221), 31–35.
https://doi.org/10.1016/j.jad.2017.05.048
Grey, I., Arora, T., Thomas, J., Saneh, A., Tohme, P., & Abi-Habib, R. (2020). The role of perceived
social support on depression and sleep during the COVID-19 pandemic. Psychiatry Research,
293(293), 113–452. https://doi.org/10.1016/j.psychres.2020.113452
Grool, A. M., Geerlings, M. I., Sigurdsson, S., Eiriksdottir, G., Jonsson, P. V., Garcia, M. E.,
Siggeirsdottir, K., Harris, T. B., Sigmundsson, T., Gudnason, V., & Launer, L. J. (2014).

67

Structural MRI correlates of apathy symptoms in older persons without dementia: AGESReykjavik Study. Neurology, 82(18), 1628–1635.
https://doi.org/10.1212/wnl.0000000000000378
Hamstra, D. A., de Kloet, E. R., Tollenaar, M., Verkuil, B., Manai, M., Putman, P., & Van der Does, W.
(2016). Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and
menstrual cycle on emotional information processing. Journal of Psychopharmacology, 30(10),
1054–1061. https://doi.org/10.1177/0269881116647504
Hamstra, D. A., De Rover, M., De Rijk, R. H., & Van der Does, W. (2014). Oral contraceptives may alter
the detection of emotions in facial expressions. European Neuropsychopharmacology, 24(11),
1855–1859. https://doi.org/10.1016/j.euroneuro.2014.08.015
Harandi, T. F., Taghinasab, M., & Nayeri, T. D. (2017). The correlation of social support with mental
health: A meta-analysis. Electronic Physician, 9(9), 5212–5222. https://doi.org/10.19082/5212
Harkness, K., Sabbagh, M., Jacobson, J., Chowdrey, N., & Chen, T. (2005). Enhanced accuracy of mental
state decoding in dysphoric college students. Cognition & Emotion, 19(7), 999–1025.
https://doi.org/10.1080/02699930541000110
Harmer, C. J., Bhagwagar, Z., Perrett, D. I., Völlm, B. A., Cowen, P. J., & Goodwin, G. M. (2003). Acute
SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers.
Neuropsychopharmacology, 28(1), 148–152. https://doi.org/10.1038/sj.npp.1300004
Harmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004). Increased Positive Versus
Negative Affective Perception and Memory in Healthy Volunteers Following Selective Serotonin
and Norepinephrine Reuptake Inhibition. American Journal of Psychiatry, 161(7), 1256–1263.
https://doi.org/10.1176/appi.ajp.161.7.1256
Hayes, A. F., & Rockwood, N. J. (2017). Regression-based statistical mediation and moderation analysis
in clinical research: Observations, recommendations, and implementation. Behaviour Research
and Therapy, 98, 39–57. https://doi.org/10.1016/j.brat.2016.11.001

68

Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020). Protracted withdrawal syndrome
after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a
large internet forum. Therapeutic Advances in Psychopharmacology, 10(10), 20–45.
https://doi.org/10.1177/2045125320980573
Herrera-Guzmán, I., Herrera-Abarca, J. E., Gudayol-Ferré, E., Herrera-Guzmán, D., Gómez-Carbajal, L.,
Peña-Olvira, M., Villuendas-González, E., & Joan, G.-O. (2010). Effects of selective serotonin
reuptake and dual serotonergic–noradrenergic reuptake treatments on attention and executive
functions in patients with major depressive disorder. Psychiatry Research, 177(3), 323–329.
https://doi.org/10.1016/j.psychres.2010.03.006
Ho, M. W.R., Chien, S. H.L., Lu, M.K., Chen, J.C., Aoh, Y., Chen, C.M., Lane, H.Y., & Tsai, C.H.
(2020). Impairments in face discrimination and emotion recognition are related to aging and
cognitive dysfunctions in Parkinson’s disease with dementia. Scientific Reports, 10(1).
https://doi.org/10.1038/s41598-020-61310-w
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015). Trends in Prescription
Drug Use Among Adults in the United States From 1999-2012. JAMA, 314(17), 1818.
https://doi.org/10.1001/jama.2015.13766
Kassam, K. S., & Mendes, W. B. (2013). The Effects of Measuring Emotion: Physiological Reactions to
Emotional Situations Depend on whether Someone Is Asking. PLoS ONE, 8(6), e64959.
https://doi.org/10.1371/journal.pone.0064959
Kitayama, S., & Ishii, K. (2002). Word and voice: Spontaneous attention to emotional utterances in two
languages. Cognition & Emotion, 16(1), 29–59. https://doi.org/10.1080/0269993943000121
Klaassen, T., Riedel, W. J., Deutz, N. P., & Van Praag, H. M. (2002). Mood congruent memory bias
induced by tryptophan depletion. Psychological Medicine, 32(1), 167–172.
https://doi.org/10.1017/s003329170100438x
Kojima, Y., Kumagai, T., Hidaka, T., Kakamu, T., Endo, S., Mori, Y., Tsukamoto, T., Sakamoto, T.,
Murata, M., Hayakawa, T., & Fukushima, T. (2018). Characteristics of facial expression

69

recognition ability in patients with Lewy body disease. Environmental Health and Preventive
Medicine, 23(1), 32. https://doi.org/10.1186/s12199-018-0723-2
Landes, A. M., Sperry, S. D., Strauss, M. E., & Geldmacher, D. S. (2001). Apathy in Alzheimer’s
Disease. Journal of the American Geriatrics Society, 49(12), 1700–1707.
https://doi.org/10.1046/j.1532-5415.2001.49282.x
Lang, P. J., Greenwald, M. K., Bradley, M. M., & Hamm, A. O. (1993). Looking at pictures: Affective,
facial, visceral, and behavioral reactions. Psychophysiology, 30(3), 261–273.
https://doi.org/10.1111/j.1469-8986.1993.tb03352.x
Levy, R., & Czernecki, V. (2006). Apathy and the basal ganglia. Journal of Neurology, 253(S7), 54–61.
https://doi.org/10.1007/s00415-006-7012-5
Levy, R., & Dubois, B. (2006). Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal
Ganglia Circuits. Cerebral Cortex, 16(7), 916–928. https://doi.org/10.1093/cercor/bhj043
Lohani, M., Payne, B. R., & Isaacowitz, D. M. (2018). Emotional coherence in early and later adulthood
during sadness reactivity and regulation. Emotion, 18(6), 789–804.
https://doi.org/10.1037/emo0000345
Lotufo, P. A., Valiengo, L., Benseñor, I. M., & Brunoni, A. R. (2012). A systematic review and metaanalysis of heart rate variability in epilepsy and antiepileptic drugs. Epilepsia, 53(2), 272–282.
https://doi.org/10.1111/j.1528-1167.2011.03361.x
Macaluso, M., & Preskorn, S. H. (2019). Antidepressants: from biogenic amines to new mechanisms of
action (Vol. 250). Cham Springer.
Macoveanu, J. (2014). Serotonergic modulation of reward and punishment: Evidence from
pharmacological fMRI studies. Brain Research, 1556(1556), 19–27.
https://doi.org/10.1016/j.brainres.2014.02.003
Marin, R. (1990). Differential diagnosis and classification of apathy. American Journal of Psychiatry,
147(1), 22–30. https://doi.org/10.1176/ajp.147.1.22

70

Marin, R. (1991). Apathy: a neuropsychiatric syndrome. The Journal of Neuropsychiatry and Clinical
Neurosciences, 3(3), 243–254. https://doi.org/10.1176/jnp.3.3.243
Marin, R., Firinciogullari, S., & Biedrzycki, R. (1993). The sources of convergence between measures of
apathy and depression. Journal of Affective Disorders, 28(1), 7–14. https://doi.org/10.1016/01650327(93)90072-R
Marin, R. S. (1997). Differential Diagnosis of Apathy and Related Disorders of Diminished Motivation.
Psychiatric Annals, 27(1), 30–33. https://doi.org/10.3928/0048-5713-19970101-08
Marin, R. S., Firinciogullari, S., & Biedrzycki, R. C. (1994). Group Differences in the Relationship
Between Apathy and Depression. The Journal of Nervous and Mental Disease, 182(4), 235–239.
https://doi.org/10.1097/00005053-199404000-00008
Martínez-Corral, M., Pagonabarraga, J., Llebaria, G., Pascual-Sedano, B., García-Sánchez, C., Gironell,
A., & Kulisevsky, J. (2010). Facial Emotion Recognition Impairment in Patients with Parkinson’s
Disease and Isolated Apathy. Parkinson’s Disease, 2010, 1–5.
https://doi.org/10.4061/2010/930627
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010). Diminished Neural Processing of
Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment.
Biological Psychiatry, 67(5), 439–445. https://doi.org/10.1016/j.biopsych.2009.11.001
Merens, W., Willem Van der Does, A. J., & Spinhoven, P. (2007). The effects of serotonin manipulations
on emotional information processing and mood. Journal of Affective Disorders, 103(1-3), 43–62.
https://doi.org/10.1016/j.jad.2007.01.032
Miller, M. W., & Patrick, C. J. (2000). Trait differences in affective and attentional responding to threat
revealed by emotional stroop interference and startle reflex modulation. Behavior Therapy, 31(4),
757–776. https://doi.org/10.1016/s0005-7894(00)80043-x
Mitterschiffthaler, M. T., Williams, S. C. R., Walsh, N. D., Cleare, A. J., Donaldson, C., Scott, J., &
Fu, C. H. Y. (2007). Neural basis of the emotional Stroop interference effect in major depression.
Psychological Medicine, 38(2), 247–256. https://doi.org/10.1017/s0033291707001523

71

Mohn, C., & Rund, B. R. (2016). Neurocognitive profile in major depressive disorders: relationship to
symptom level and subjective memory complaints. BMC Psychiatry, 16(1).
https://doi.org/10.1186/s12888-016-0815-8
Montoya‐Murillo, G., Ibarretxe‐Bilbao, N., Peña, J., & Ojeda, N. (2019). The impact of apathy on
cognitive performance in the elderly. International Journal of Geriatric Psychiatry, 34(5), 657–
665. https://doi.org/10.1002/gps.5062
Murphy, F., Smith, K., Cowen, P., Robbins, T., & Sahakian, B. (2002). The effects of tryptophan
depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology,
163(1), 42–53. https://doi.org/10.1007/s00213-002-1128-9
Murphy, K. (2000). Differentiation of states and causes of apathy. The Neuropsychology of Emotion, 340.
Neumeister, A. (2003). Tryptophan depletion, serotonin, and depression: where do we stand?
Psychopharmacology Bulletin, 37(4), 99–115.
Nielsen, S. E., Segal, S. K., Worden, I. V., Yim, I. S., & Cahill, L. (2013). Hormonal contraception use
alters stress responses and emotional memory. Biological Psychology, 92(2), 257–266.
https://doi.org/10.1016/j.biopsycho.2012.10.007
Oliver, A., Pile, V., Elm, D., & Lau, J. Y. F. (2019). The Cognitive Neuropsychology of Depression in
Adolescents. Current Behavioral Neuroscience Reports, 6(4), 227–235.
https://doi.org/10.1007/s40473-019-00187-0
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R.
(2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit
emotional responses? The International Journal of Neuropsychopharmacology, 5(02).
https://doi.org/10.1017/s1461145702002870
Pahnke, R., Mau-Moeller, A., Junge, M., Wendt, J., Weymar, M., Hamm, A. O., & Lischke, A. (2019).
Oral Contraceptives Impair Complex Emotion Recognition in Healthy Women. Frontiers in
Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01041

72

Paunovic, N., Lundh, L.G., & Öst, L.G. (2002). Attentional and memory bias for emotional information
in crime victims with acute posttraumatic stress disorder (PTSD). Journal of Anxiety Disorders,
16(6), 675–692. https://doi.org/10.1016/s0887-6185(02)00136-6
Pearson, N. C. S. (2009). Advanced clinical solutions for WAIS-IV and WMS-IV: Administration and
scoring manual. San Antonio: The Psychological Corporation.
Persad, S. M., & Polivy, J. (1993). Differences between depressed and nondepressed individuals in the
recognition of and response to facial emotional cues. Journal of Abnormal Psychology, 102(3),
358–368. https://doi.org/10.1037/0021-843x.102.3.358
Plowden, K. O. (2019). Antidepressant-Related Apathy: Implications for Practice. The Journal for Nurse
Practitioners, 15(2), 164–170. https://doi.org/10.1016/j.nurpra.2018.10.018
Pluck, G. C., & Brown, R. G. (2002). Apathy in Parkinson’s disease. Journal of Neurology, Neurosurgery
& Psychiatry, 73(6), 636–642. https://doi.org/10.1136/jnnp.73.6.636
Price, J., Cole, V., & Goodwin, G. M. (2009). Emotional side-effects of selective serotonin reuptake
inhibitors: qualitative study. British Journal of Psychiatry, 195(3), 211–217.
https://doi.org/10.1192/bjp.bp.108.051110
Price, J., Cole, V., Doll, H., & Goodwin, G. M. (2012). The Oxford Questionnaire on the Emotional Sideeffects of Antidepressants (OQuESA): Development, validity, reliability and sensitivity to
change. Journal of Affective Disorders, 140(1), 66–74. https://doi.org/10.1016/j.jad.2012.01.030
Radakovic, R., & Abrahams, S. (2014). Developing a new apathy measurement scale: Dimensional
Apathy Scale. Psychiatry Research, 219(3), 658–663.
https://doi.org/10.1016/j.psychres.2014.06.010
Rao, N. P., Arasappa, R., Reddy, N. N., Venkatasubramanian, G., & Reddy, Y. C. J. (2010). Emotional
interference in obsessive–compulsive disorder: A neuropsychological study using optimized
emotional Stroop test. Psychiatry Research, 180(2-3), 99–104.
https://doi.org/10.1016/j.psychres.2009.10.017

73

Rascati, K., Godley, P., & Pham, H. (2001). Evaluation of Resources Used To Treat Adverse Events of
Selective Serotonin Reuptake Inhibitor Use. Journal of Managed Care Pharmacy, 7(5), 402–406.
https://doi.org/10.18553/jmcp.2001.7.5.402
Read, J., & Williams, J. (2018). Adverse Effects of Antidepressants Reported by a Large International
Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. Current Drug Safety, 13(3),
176–186. https://doi.org/10.2174/1574886313666180605095130
Reinblatt, S. P., & Riddle, M. A. (2006). Selective Serotonin Reuptake Inhibitor-Induced Apathy: A
Pediatric Case Series. Journal of Child and Adolescent Psychopharmacology, 16(1-2), 227–233.
https://doi.org/10.1089/cap.2006.16.227
Robert, P. H., Clairet, S., Benoit, M., Koutaich, J., Bertogliati, C., Tible, O., Caci, H., Borg, M., Brocker,
P., & Bedoucha, P. (2002). The Apathy Inventory: assessment of apathy and awareness in
Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. International Journal of
Geriatric Psychiatry, 17(12), 1099–1105. https://doi.org/10.1002/gps.755
Roohafza, H., Afshar, H., Keshteli, A., Mohammadi, N., Feizi, N., Taslimi, M., & Adibi, P. (2014).
What’s the role of perceived social support and coping styles in depression and anxiety? Journal
of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences,
19(10), 944.
Rosen, R. C., Lane, R. M., & Menza, M. (1999). Effects of SSRIs on Sexual Function. Journal of Clinical
Psychopharmacology, 19(1), 67–85. https://doi.org/10.1097/00004714-199902000-00013
Ros, L., Satorres, E., Fernández-Aguilar, L., Delhom, I., López-Torres, J., Latorre, J. M., & Melendez, J.
C. (2021). Differential effects of faces and words in cognitive control in older adults with and
without major depressive disorder: An emotional Stroop task study. Applied Neuropsychology:
Adult, 1–10. https://doi.org/10.1080/23279095.2021.1927037
Sansone, R., & Sansone, L. (2010). SSRI-induced Indifference. Psychiatry (Edgmont), 7(10), 14.
Scherer, K. R. (2005). What are emotions? And how can they be measured? Social Science Information,
44(4), 695–729. https://doi.org/10.1177/0539018405058216

74

Schmid, M., & Hammer, A. (2013). Cognitive function in first episode major depressive disorder: Poor
inhibition and semantic fluency performance. Cognitive Neuropsychiatry, 18(6), 515–530.
https://doi.org/10.1080/13546805.2012.754748
Sen, A., Capelli, V., & Husain, M. (2018). Cognition and dementia in older patients with epilepsy. Brain,
141(6), 1592–1608. https://doi.org/10.1093/brain/awy022
Serra-Mestres, J., & Ring, H. (1999). Vulnerability to emotionally negative stimuli in Parkinson’s
disease: an investigation using the Emotional Stroop task. Neuropsychiatry, 12(1), 52–57.
Shenal, B. V., Harrison, D. W., & Demaree, H. A. (2003). The neuropsychology of depression: a
literature review and preliminary model. Neuropsychology Review, 13(1), 33–42.
https://doi.org/10.1023/a:1022300622902
Snyder, H. R. (2013). Major depressive disorder is associated with broad impairments on
neuropsychological measures of executive function: A meta-analysis and review. Psychological
Bulletin, 139(1), 81–132. https://doi.org/10.1037/a0028727
Sockeel, P. (2006). The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying
apathy: validation in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry,
77(5), 579–584. https://doi.org/10.1136/jnnp.2005.075929
Spies, M., Kraus, C., Geissberger, N., Auer, B., Klöbl, M., Tik, M., Stürkat, I-L., Hahn, A., Woletz, M.,
Pfabigan, D. M., Kasper, S., Lamm, C., Windischberger, C., & Lanzenberger, R. (2017). Default
mode network deactivation during emotion processing predicts early antidepressant response.
Translational Psychiatry, 7(1), e1008–e1008. https://doi.org/10.1038/tp.2016.265
Takahashi, H., Yahata, N., Koeda, M., Takano, A., Asai, K., Suhara, T., & Okubo, Y. (2005). Effects of
dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI
study. NeuroImage, 27(4), 991–1001. https://doi.org/10.1016/j.neuroimage.2005.05.039
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006). Early Onset of Selective Serotonin
Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis. Archives of
General Psychiatry, 63(11), 1217. https://doi.org/10.1001/archpsyc.63.11.1217

75

Tocco, C., & Brumbaugh, C. C. (2019). SSRIs may not be the most “attractive” way to treat depression:
how antidepressants affect romantic attraction. Journal of Behavioral Science & Psychology,
2(4).
Tranter, R., Bell, D., Gutting, P., Harmer, C., Healy, D., & Anderson, I. M. (2009). The effect of
serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
Journal of Affective Disorders, 118(1-3), 87–93. https://doi.org/10.1016/j.jad.2009.01.028
Turner, R., & Brown, R. (2010). Social support and mental health: A handbook of the study of mental
health. Social Contexts, Theories, and Systems, 2, 200–212.
Uchino, B. N., Cacioppo, J. T., & Kiecolt-Glaser, J. K. (1996). The relationship between social support
and physiological processes: A review with emphasis on underlying mechanisms and
implications for health. Psychological Bulletin, 119(3), 488–531. https://doi.org/10.1037/00332909.119.3.488
Valjent, E., Mitchell, J. M., Besson, M.-J., Caboche, J., & Maldonado, R. (2002). Behavioural and
biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine. British
Journal of Pharmacology, 135(2), 564–578. https://doi.org/10.1038/sj.bjp.0704479
Veiel, H. O. F., & Baumann, U. (2016). The meaning and measurement of social support. Taylor &
Francis.
Vythilingam, M., Blair, K. S., McCaffrey, D., Scaramozza, M., Jones, M., Nakic, M., Mondillo, K.,
Hadd, K., Bonne, O., Mitchell, D. G., Pine, D. S., Charney, D. S., & Blair, R. J. (2007). Biased
emotional attention in post-traumatic stress disorder: a help as well as a hindrance? Psychological
Medicine, 37(10), 1445–1455. https://doi.org/10.1017/s003329170700092x
Walsh, A., McDowall, J., & Grimshaw, G. M. (2010). Hemispheric specialization for emotional word
processing is a function of SSRI responsiveness. Brain and Cognition, 74(3), 332–340.
https://doi.org/10.1016/j.bandc.2010.09.003

76

Wingenfeld, K., Mensebach, C., Driessen, M., Bullig, R., Hartje, W., & Beblo, T. (2006). Attention Bias
towards Personally Relevant Stimuli: The Individual Emotional Stroop Task. Psychological
Reports, 99(3), 781–793. https://doi.org/10.2466/pr0.99.3.781-793
Wongpakaran, N., Van Reekum, R., Wongpakaran, T., & Clarke, D. (2006). Selective serotonin reuptake
inhibitor use associates with apathy among depressed elderly: a case-control study. Annals of
General Psychiatry, 5(S1). https://doi.org/10.1186/1744-859x-5-s1-s83
Yeager, C. A., & Hyer, L. (2008). Apathy in Dementia: Relations with Depression, Functional
Competence, and Quality of Life. Psychological Reports, 102(3), 718–722.
https://doi.org/10.2466/pr0.102.3.718-722
Young, K. D., Friedman, E. S., Collier, A., Berman, S. R., Feldmiller, J., Haggerty, A. E., Thase, M. E.,
& Siegle, G. J. (2020). Response to SSRI intervention and amygdala activity during selfreferential processing in major depressive disorder. NeuroImage: Clinical, 28, 102388.
https://doi.org/10.1016/j.nicl.2020.102388
Yuen, G. S., Gunning-Dixon, F. M., Hoptman, M. J., AbdelMalak, B., McGovern, A. R., Seirup, J. K., &
Alexopoulos, G. S. (2014). The salience network in the apathy of late-life depression.
International Journal of Geriatric Psychiatry, 29(11), 1116–1124.
https://doi.org/10.1002/gps.4171
Zahodne, L. B., & Tremont, G. (2012). Unique effects of apathy and depression signs on cognition and
function in amnestic mild cognitive impairment. International Journal of Geriatric Psychiatry,
28(1), 50–56. https://doi.org/10.1002/gps.3789

77

